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Background: Behaviour problems emerge early in childhood and place children at risk for later
psychopathology.
Objectives: To evaluate the clinical effectiveness and cost-effectiveness of a parenting intervention to
prevent enduring behaviour problems in young children.
Design: A pragmatic, assessor-blinded, multisite, two-arm, parallel-group randomised controlled trial.
Setting: Health visiting services in six NHS trusts in England.
Participants: A total of 300 at-risk children aged 12–36 months and their parents/caregivers.
Interventions: Families were allocated in a 1 : 1 ratio to six sessions of Video-feedback Intervention to
promote Positive Parenting and Sensitive Discipline (VIPP-SD) plus usual care or usual care alone.
Main outcome measures: The primary outcome was the Preschool Parental Account of Children’s
Symptoms, which is a structured interview of behaviour symptoms. Secondary outcomes included
caregiver-reported total problems on the Child Behaviour Checklist and the Strengths and Difficulties
Questionnaire. The intervention effect was estimated using linear regression. Health and social care
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service use was recorded using the Child and Adolescent Service Use Schedule and cost-effectiveness
was explored using the Preschool Parental Account of Children’s Symptoms.
Results: In total, 300 families were randomised: 151 to VIPP-SD plus usual care and 149 to usual
care alone. Follow-up data were available for 286 (VIPP-SD, n = 140; usual care, n = 146) participants
and 282 (VIPP-SD, n = 140; usual care, n = 142) participants at 5 and 24 months, respectively. At the
post-treatment (primary outcome) follow-up, a group difference of 2.03 on Preschool Parental Account
of Children’s Symptoms (95% confidence interval 0.06 to 4.01; p = 0.04) indicated a positive treatment
effect on behaviour problems (Cohen’s d = 0.20, 95% confidence interval 0.01 to 0.40). The effect was
strongest for children’s conduct [1.61, 95% confidence interval 0.44 to 2.78; p = 0.007 (d = 0.30, 95%
confidence interval 0.08 to 0.51)] versus attention deficit hyperactivity disorder symptoms [0.29, 95%
confidence interval –1.06 to 1.65; p = 0.67 (d = 0.05, 95% confidence interval –0.17 to 0.27)]. The Child
Behaviour Checklist [3.24, 95% confidence interval –0.06 to 6.54; p = 0.05 (d = 0.15, 95% confidence
interval 0.00 to 0.31)] and the Strengths and Difficulties Questionnaire [0.93, 95% confidence interval
–0.03 to 1.9; p = 0.06 (d = 0.18, 95% confidence interval –0.01 to 0.36)] demonstrated similar positive
treatment effects to those found for the Preschool Parental Account of Children’s Symptoms. At 24 months,
the group difference on the Preschool Parental Account of Children’s Symptoms was 1.73 [95% confidence
interval –0.24 to 3.71; p = 0.08 (d = 0.17, 95% confidence interval –0.02 to 0.37)]; the effect remained
strongest for conduct [1.07, 95% confidence interval –0.06 to 2.20; p = 0.06 (d = 0.20, 95% confidence
interval –0.01 to 0.42)] versus attention deficit hyperactivity disorder symptoms [0.62, 95% confidence
interval –0.60 to 1.84; p = 0.32 (d = 0.10, 95% confidence interval –0.10 to 0.30)], with little evidence
of an effect on the Child Behaviour Checklist and the Strengths and Difficulties Questionnaire. The
primary economic analysis showed better outcomes in the VIPP-SD group at 24 months, but also higher
costs than the usual-care group (adjusted mean difference £1450, 95% confidence interval £619 to £2281).
No treatment- or trial-related adverse events were reported. The probability of VIPP-SD being cost-effective
compared with usual care at the 24-month follow-up increased as willingness to pay for improvements
on the Preschool Parental Account of Children’s Symptoms increased, with VIPP-SD having the higher
probability of being cost-effective at willingness-to-pay values above £800 per 1-point improvement on
the Preschool Parental Account of Children’s Symptoms.
Limitations: The proportion of participants with graduate-level qualifications was higher than among the
general public.
Conclusions: VIPP-SD is effective in reducing behaviour problems in young children when delivered by
health visiting teams. Most of the effect of VIPP-SD appears to be retained over 24 months. However,
we can be less certain about its value for money.
Trial registration: Current Controlled Trials ISRCTN58327365.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 29.
See the NIHR Journals Library website for further project information.
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Behaviour problems in young children are common and are linked to mental and physical healthproblems, and educational and social difficulties. An important factor that influences the development
of behaviour problems is the quality of care that children receive from their caregivers. This study aimed
to test if a six-session parenting programme [called Video-feedback Intervention to promote Positive
Parenting and Sensitive Discipline (VIPP-SD)] reduced behaviour problems in children aged 1 or 2 years
who were showing early signs of behaviour problems (e.g. restlessness, impulsivity, tantrums and
aggression). VIPP-SD supports caregivers in responding to their child’s communication and behaviour.
A total of 300 families participated. All families continued to access usual health-care services (e.g.
health visitors and general practitioners), but half of the families were randomly allocated to also receive
the VIPP-SD programme. We visited all families when the study started, and at 5 and 24 months to
see if the children whose families received VIPP-SD showed fewer behaviour problems. We measured
the children’s behaviour by completing interviews and questionnaires with their caregivers. We also
analysed whether or not VIPP-SD was good value for money compared with existing services. We did
this by comparing the cost of all of the standard health and community services that families accessed
during their time in the study, taking account of the impact that VIPP-SD had on children’s behaviour.
The children in the VIPP-SD group had lower levels of behaviour problems following the programme
than children whose parents did not receive the programme. On average, VIPP-SD children scored
2 points lower on the main measure of behaviour; an example difference would be tantrums being
rated as mild rather than severe. By the 2-year visit, the VIPP-SD children continued to show lower
levels of behaviour problems. It is less clear whether or not VIPP-SD is good value for money, as this
depends on how much money policy-makers are willing to invest for reductions in behaviour problems.
Overall, there is strong evidence that the VIPP-SD programme is effective in reducing behaviour
problems in the short term. Most of this benefit appears to be maintained for the following 2 years.
However, we are less certain about the long-term effect and the VIPP-SD’s value for money.
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As many as 1 in 10 children experience behaviour problems, and enduring problems can undermine
children’s health, social and educational outcomes across their life course. As well as the distress that
these issues can cause for children and families, there are considerable costs to society. An important
factor that influences the development of behaviour problems is the quality and style of early parental
care that children experience. Parenting strategies can lead to improvements in child behaviour;
systematic reviews have shown that parenting programmes are effective in reducing behaviour
problems in preschool- and school-aged children. However, there are very few effective early
psychological interventions available. Intervening earlier in childhood before problems become
established could increase the impact that parenting programmes have on children and families.
An evidence-based programme that is suitable for use with children aged ≥ 12 months is the Video-
feedback Intervention to promote Positive Parenting and Sensitive Discipline (VIPP-SD) programme.
VIPP-SD has been developed in a systematic way, has been tested in 12 randomised controlled trials
and has been shown to be effective in improving parenting practices and child behaviour outcomes.
However, the intervention is yet to be tested in a routine health service context in the UK.
The Healthy Start, Happy Start study was a pragmatic, assessor-blinded, multisite, two-arm, parallel-
group randomised controlled trial to test the clinical effectiveness and cost-effectiveness of VIPP-SD
for parents of young children (aged 12–36 months) who were at risk of developing enduring
behaviour problems.
Objectives
The objectives were to:
l undertake a randomised controlled trial to evaluate whether or not a brief parenting intervention
(VIPP-SD) leads to lower levels of behaviour problems in young children who are at a high risk of
developing these problems, compared with usual care in the NHS




The study was a pragmatic, assessor-blinded, multisite, two-arm, parallel-group randomised
controlled trial.
Setting
The participants were recruited from health visiting and community services in six UK NHS trusts.
Participants
The participants were 300 children aged 12–36 months who demonstrated elevated behaviour
difficulties (as measured by a parent-reported screening questionnaire) and their caregiver(s).
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Target population
Target participants were children aged 12–36 months who scored in the top 20% for behaviour
problems on the parent-reported Strengths and Difficulties Questionnaire. We excluded children or
parents with a severe sensory impairment, learning disability or language limitation that was sufficient
to preclude participation in the trial. We also excluded children with a participating sibling, those
whose parents were actively involved in family court proceedings and those participating in a closely
related research study and/or receiving an individual video-feedback-based intervention.
Randomisation
We randomly allocated participants in a 1 : 1 ratio to either VIPP-SD or usual care, stratified by
recruitment site and the number of participating caregivers (one vs. two).
Intervention
All families continued to access usual care, which comprised mainly general practitioner and health
visiting services. Families allocated to the VIPP-SD group were offered six home-based, fortnightly
sessions of 1–2 hours’ duration. Each visit was composed of two parts. In the first part, therapists
recorded videos of parents during everyday interactions with their children. In the second part of the
visit, therapists provided structured feedback based on the intervention manual and the contents
of the interaction. This feedback aimed to promote parents’ sensitivity; and their capacity to identify their
child’s attachment cues and exploratory behaviour, and to respond to their child appropriately, as well as
providing sensitive discipline, which involves a consistent but non-harsh response to challenging behaviour.
The manualised intervention was delivered predominantly by health professionals, including health
visitors, community nursery nurses and psychologists, following 5 days of training and a supervised
practice case. Therapists received ongoing clinical supervision throughout intervention delivery.
Outcome measurements
Baseline information
We collected demographic data at baseline on parents’ sex, age, ethnicity, educational attainment,
employment status and relationship status. We also collected data on childrens’ sex, age and ethnicity.
Baseline measures of all outcome data were also collected.
Primary clinical outcome
The primary outcome was severity of behaviour problems (as measured by the Preschool Parental
Account of Children’s Symptoms interview) at the 5-month follow-up.
Secondary clinical outcomes
Key secondary outcomes included severity of behaviour problems, measured using the Preschool Parental
Account of Children’s Symptoms interview at the 24-month follow-up, as well as parent-reported child
behaviour, measured at the 5- and 24-month follow-ups using the Child Behaviour Checklist and the
Strengths and Difficulties Questionnaire. Additional secondary outcomes included parent-reported
measures of parenting practices (Parenting Scale), parent mood (Patient Health Questionnaire-9) and
anxiety (Generalised Anxiety Disorder-7) and couple functioning (Revised Dyadic Adjustment Scale) at
the 5- and 24-month follow-ups.
Economic measures
Health and social care service use was recorded using the Child and Adolescent Service Use Schedule.
In the short term (‘within-trial’), the cost-effectiveness of the VIPP-SD was explored in terms of the
primary outcome measure (Preschool Parental Account of Children’s Symptoms) at the 24-month
follow-up and a cost–consequences analysis was carried out. The cost–consequences analysis outlined
costs alongside the key secondary outcome measures (Child Behaviour Checklist and Strengths and
Difficulties Questionnaire) to explore potential economic impacts of the intervention on outcomes
more broadly.
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Sample size
A sample size of 300 participants was selected to provide between 80% and 90% power to detect
standardised effect sizes of 0.36 and 0.42, respectively, at a 5% level of statistical significance and
assuming a 20% attrition rate.
Statistical methods and analyses.
Clinical outcome analyses
We conducted the primary analysis using intention to treat for primary and secondary outcomes.
We also undertook secondary analysis to estimate the effect of receiving the intervention using
complier-average causal effects analysis on the primary outcome and key secondary outcomes. In the
primary analysis, we estimated the effects of the VIPP-SD programme by comparing the VIPP-SD and
usual-care groups using linear regression, which adjusted for baseline levels of the same outcome,
treatment centre, length of follow-up, age of the child and number of participating caregivers.
We undertook a sensitivity analysis to assess the impact of missing data and adjusted for the length
of follow-up. For the primary outcome (measured using the Preschool Parental Account of Children’s
Symptoms), we used multiple imputation to fill in missing items in the Preschool Parental Account of
Children’s Symptoms scales (as some items were unrateable for some children) and we used multiple
imputation for the families where follow-up data were not available (5% at the 5-month follow-up,
6% at the 24-month follow-up).
Economic analyses
Cost-effectiveness was assessed at the 24-month follow-up through the calculation of incremental
cost-effectiveness ratios (the additional cost of one intervention compared with another divided by the
additional effect) and using the net monetary benefit approach. Uncertainty around the mean estimates
of cost and outcome was explored using bootstrapping and plotting the bootstrap iterations onto a
cost-effectiveness plane for interpretation. Cost-effectiveness acceptability curves were constructed
to examine the probability of VIPP-SD being cost-effective compared with usual care for a range of
possible values of willingness to pay per unit improvement in outcome. All economic analyses were
adjusted in line with the clinical analyses and based on multiply imputed data sets of total costs and
outcomes using chained equations and predictive mean matching. Sensitivity analyses explored the
impact of missing data, influential outliers and the selected end point, repeating the analysis for
the 5-month follow-up.
Results
Between July 2015 and July 2017, we assessed 2248 families for eligibility. In total, 1430 families were
ineligible, 518 families did not progress to the trial (declined/could not be contacted) and 300 families
were randomised. Of the randomised families, 151 (50%) were randomly allocated to the intervention
(VIPP-SD) group and 149 (50%) were randomly allocated to the usual-care group. Participant-level
characteristics at baseline were well balanced between groups. Of the 151 families randomised to
receive the intervention, 129 (85%) completed at least four VIPP-SD sessions (the compliance cut-off
point for treatment adherence). Retention was high, with primary outcome data available for 286
(95%) participants at the 5-month follow-up and 282 (94%) participants at the 24-month follow-up.
On the primary outcome (Preschool Parental Account of Children’s Symptoms at 5 months by intention-
to-treat analysis), we found that VIPP-SD was superior to usual care [mean 28.80 (standard deviation
9.2) vs. 30.31 (standard deviation 9.9); adjusted mean difference 2.03 (95% confidence interval 0.06 to
4.01); p = 0.04], indicating a positive treatment effect (Cohen’s d = 0.20, 95% confidence interval 0.01 to
0.40). VIPP-SD was found to be superior to usual care on the conduct problems subscale of the primary
outcome (difference 1.61, 95% confidence interval 0.44 to 2.78; p = 0.007, d = 0.30, 95% confidence
interval 0.08 to 0.51), but not the hyperactivity subscale (difference 0.29, 95% confidence interval
–1.06 to 1.65; p = 0.67, d = 0.05, 95% confidence interval –0.17 to 0.27). The positive effect of VIPP-SD
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on the Preschool Parental Account of Children’s Symptoms total score at 5-month follow-up was robust
to sensitivity analyses. The complier-average causal effects analysis on the primary outcome of child
behaviour showed higher estimated treatment effects in those with acceptable treatment adherence,
that is those who received at least four core VIPP-SD sessions (Preschool Parental Account of Children’s
Symptoms difference increased from 2.03 to 2.59, 95% confidence interval 0.24 to 4.94; p = 0.03, d= 0.26,
95% confidence interval 0.02 to 0.50). At the 24-month follow-up, there was evidence of a sustained
intention-to-treat treatment effect favouring the VIPP-SD group (difference 1.73, 95% confidence interval
–0.24 to 3.71; p = 0.08, d = 0.17, 95% confidence interval –0.02 to 0.37). Again, the difference was higher
for the conduct subscale (difference 1.07, 95% confidence interval –0.06 to 2.2; p = 0.06, d = 0.20,
95% confidence interval –0.01 to 0.42) than for the hyperactivity scale (difference 0.62, 95% confidence
interval –0.60 to 1.84; p = 0.32, d = 0.10, 95% confidence interval –0.10 to 0.30). Those who received at
least four VIPP-SD sessions continued to show a greater improvement in behaviour (complier-average
casual effects Preschool Parental Account of Children’s Symptoms difference increased from 1.73 to
1.96, 95% confidence interval –0.30 to 4.23; p = 0.09, d = 0.20, 95% confidence interval –0.03 to 0.43).
On the main secondary outcomes (total scores of the Child Behaviour Checklist and Strengths and
Difficulties Questionnaire), the results indicated a positive direction of effect favouring the VIPP-SD
group at the 5-month follow-up, but less evidence of a sustained effect at 24-month follow-up. We
found no appreciable evidence of differences between groups on other included secondary outcomes
at the 5- or 24-month follow-up.
No treatment- or trial-related adverse events were reported. There were no group differences in the
reporting of unrelated adverse events.
Mean total costs were significantly higher in the VIPP-SD group than in the usual-care group at
the 24-month follow-up (adjusted mean difference £1450, 95% confidence interval £619 to £2281;
p = 0.001) and were driven by the cost of the intervention (mean cost £1466 per family). However,
VIPP-SD was also associated with Preschool Parental Account of Children’s Symptoms scores that
favoured the intervention, thus generating a trade-off, with VIPP-SD being more costly but also more
effective than usual care. The probability of VIPP-SD being cost-effective compared with usual care
increased as willingness to pay for improvements in Preschool Parental Account of Children’s Symptoms
score increased, with VIPP-SD having higher probability of being cost-effective at willingness-to-pay
values of approximately £800 per 1-point improvement in Preschool Parental Account of Children’s
Symptoms score (equivalent to 0.10 standard deviation) and above. In theory, this would be equivalent
to approximately £7920 for one standard deviation improvement. Because the Preschool Parental
Account of Children’s Symptoms is not associated with a willingness-to-pay threshold to support
decision-making, it is not possible to come to any firm conclusions about the relative cost-effectiveness
of VIPP-SD in the short term. These results were robust to changes in assumptions in sensitivity analyses
(complete case, excluding outliers and analysis at the 5-month follow-up).
Conclusions
We found evidence that a brief, home-based intervention, VIPP-SD, was more effective than usual care
in reducing behaviour problems in this group of children aged 1 or 2 years. Evidence of superiority
was found for the primary outcome (the interview-based Preschool Parental Account of Children’s
Symptoms assessment) at the 5-month post-treatment assessment. The findings were strongest on
the conduct problems scale of the Preschool Parental Account of Children’s Symptoms assessment,
rather than the attention deficit hyperactivity disorder/hyperkinesis scale, which is in keeping with the
sensitive discipline focus of the VIPP-SD intervention, which targets conduct problems. Our results are
consistent with a meta-analysis of the VIPP-SD intervention, which demonstrated similar effect sizes
for child behaviour problems [Juffer F, Bakermans-Kranenburg MJ, van Ijzerdoorn MH. Video-feedback
Intervention to Promote Positive Parenting and Sensitive Discipline (VIPP-SD): Development and
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxiv
Meta-Analytical Evidence of Its Effectiveness. In Steele H, Steele M, editors. Handbook of Attachment-
based Interventions. 1st edn. New York, NY: Guildford; 2017. pp. 1–26]. Thus, it is noteworthy that the
present study demonstrates that this effect is robust in a routine health service context. Our best
estimate is that most of the effect of VIPP-SD is retained over 24 months. However, we are less certain
about its value for money.
Implications for health care and future research
The results of this research show that the VIPP-SD intervention can be delivered successfully in routine
NHS care to specified groups of children with behaviour problems, and that those with particularly high
levels of behaviour problems may benefit most. Furthermore, these problems can be identified using a
simple, brief screening questionnaire. There is significant scope for this intervention to be incorporated
in routine practice.
Key implications for future research include the following. First, further study is needed to assess
the potential longer-term outcomes of early interventions such as VIPP-SD. Second, further study is
needed to investigate whether or not the benefits of this early intervention can be enhanced with the
addition of booster sessions or other later intervention. Third, future research is needed to elucidate the
mechanisms underlying effective early interventions such as VIPP-SD and for whom the intervention
may work best.
Early intervention represents a substantial opportunity for the future positive development of young
children and a lack of effective interventions is a key challenge. The results of this study provide a
significant step forward and represent a new opportunity for effective early childhood intervention to
prevent enduring mental health problems.
Trial registration
This trial is registered as ISRCTN58327365.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 29.
See the NIHR Journals Library website for further project information.
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Behaviour problems and their impact on health and development
Behaviour problems are among the most common mental health problems in young children, affecting
an estimated 5–10% of children.1,2 These disorders typically include attention deficit hyperactivity
disorder (ADHD), conduct disorder and oppositional defiant disorder,3 and are a key concern for the
NHS. According to the National Institute for Health and Care Excellence (NICE),4 ≈ 30% of a typical
general practitioner’s (GP’s) child consultations are for behaviour problems and 45% of community
child health referrals are for behaviour disturbances. Behaviour problems are also one of the most
common reasons for children to be referred to mental health services.4,5
Behaviour problems are distinct in having one of the earliest onsets of mental health problems, with
increasing research indicating that early symptoms can be identified in children aged 1 and 2 years.6
Where problems endure over time, they can give rise to poorer educational attainment and physical
health, as well as elevated risk of psychiatric disorders, substance misuse, antisocial behaviour and
criminality.2,5,7,8 In addition to the distress caused to individuals and families, there is a considerable
cost to society through the health-care, social care and criminal justice systems.9 Recent estimates
put the lifetime costs of support for a child with conduct disorder at £280,000.10
Interventions for behaviour problems
The quality of the early parental care that children experience has been causally linked to the
development of behaviour problems. Where children experience low levels of sensitive parenting
behaviour and greater use of harsh discipline, they are at a high risk of developing behaviour problems.11
Consequently, these parenting behaviours, sensitivity and discipline, represent the key targets of
most early intervention programmes in the UK, based on attachment theory and social learning
theory, respectively.12,13
There is an established evidence base demonstrating positive effects of parenting interventions for
preschool- and school-aged children’s behaviour. An umbrella meta-analysis14 of 26 meta-analyses
identified 411 studies of parenting interventions for children with externalising behaviours. The
authors found that those studies that reported on externalising behaviour showed evidence of
moderate positive effects. A recent meta-analysis15 of 154 randomised controlled trials (RCTs) also
found a moderate positive effect of parenting interventions on children’s behaviour. The authors also
reported an individual participant data meta-analysis of 13 RCTs of a specific parenting intervention,
Incredible Years, which showed similar positive effects on conduct problems and ADHD symptoms.15
Estimates of the cost savings associated with such programmes suggest that parenting interventions
could provide savings of approximately £16,425 per family over 25 years.16 As most programmes
target preschool- (aged 3 or 4 years) and school-aged children, we know less about the effectiveness
of programmes delivered in infancy and toddlerhood. Intervening earlier in childhood could be more
effective both clinically and economically, provided that there is reliable identification of children at
risk, as there is increased opportunity to intercept psychopathology before it becomes embedded and
to reduce the burden of suffering experienced by families.17
An evidence-based programme that can be delivered from aged 12 months is the Video-feedback
Intervention to promote Positive Parenting and Sensitive Discipline (VIPP-SD) programme.18,19 VIPP-SD
represents a powerful combination of social learning theory and attachment theory, and targets the two
key parenting behaviours: sensitivity and discipline. The goal of the intervention is to promote parents’
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sensitivity (i.e. their capacity to identify their child’s attachment cues and exploratory behaviour, and
respond to them appropriately) and sensitive discipline, which involves a consistent but non-harsh
response to challenging behaviour. The VIPP-SD programme has been developed systematically and has
been tested in 12 RCTs20–31 in a range of clinical and non-clinical populations. A recent meta-analysis32 of
these trials demonstrated combined positive effects on caregivers’ sensitivity and children’s behaviour
problems. However, VIPP-SD has yet to be tested in a routine health service context in the UK.
Rationale for the research
Early intervention has the potential to improve behaviour problems before they become established,
which could yield cascading benefits for children’s outcomes across their life course. Indeed, early
intervention has become a key priority of global and domestic policy.33–35 However, there are few
effective early psychological interventions that target behaviour problems in very young children.36
The literature also demonstrates that no single programme or service delivery method has been shown
to be a panacea for the varied challenges that families face.37 Rather, effective early intervention
for children at risk of behaviour problems is likely to require the identification of a range of efficient
and repeated interventions at different developmental stages.38 This is in keeping with global policy
recommendations on the importance of staged and developmentally informed intervention across early
childhood that is grounded in nurturing caregiving.39 Successful early intervention, therefore, first
requires effective programmes that can target behaviour problems at their earliest onset in children
aged 1 and 2 years. The Healthy Start, Happy Start study was designed to address this gap by testing
whether or not a brief parenting intervention (VIPP-SD) could be effective in preventing enduring
behaviour problems in children aged 1 and 2 years in a pragmatic health service context.
Aims and objectives
The aim of the Healthy Start, Happy Start study was to evaluate the clinical effectiveness and
cost-effectiveness of a brief early parenting intervention to prevent enduring behaviour problems in
young children aged 12–36 months.
The objectives were to:
l undertake a RCT to evaluate whether or not a brief parenting intervention (VIPP-SD) leads to lower
levels of behaviour problems in young children who are at high risk of developing these problems,
compared with usual care in the NHS
l undertake an economic evaluation to assess the cost-effectiveness of the intervention compared
with usual care.
INTRODUCTION




The Healthy Start, Happy Start study was a pragmatic, assessor-blinded, multisite, two-arm, parallel-
group RCT, to test the clinical effectiveness and cost-effectiveness of a brief parenting intervention
(VIPP-SD) for parents of young children (aged 12–36 months) at risk of behaviour difficulties.
VIPP-SD was predominantly delivered by trained therapists through NHS health visiting teams and
was compared with receiving usual care alone.
Ethics and governance
Ethics approval for the study was given by Riverside Research Ethics Committee (14/LO/2071), which
is part of the NHS Research Ethics Service. The trial was registered with the Integrated Research
Approval System (IRAS) under the reference number 160786 and the National Institute for Health
Research (NIHR) Clinical Research Network (CRN) Portfolio under the reference number 18423. The
trial was registered with the International Standard Randomised Controlled Trial Number (ISRCTN)
registry as number ISRCTN58327365. Approval for the study to be conducted within participating
NHS sites was obtained from the NHS Health Research Authority (HRA). Local NHS permissions were
also given for each recruitment site. The trial was conducted in accordance with the Declaration of
Helsinki,40 UK Policy Framework for Health and Social Care Research41 and Imperial Clinical Trials Unit
(ICTU) standard operating procedures.
Participants
Participants were children aged 12–36 months who demonstrated behaviour problems and
their caregiver(s).
Inclusion criteria
To be eligible to participate, families had to meet the following inclusion criteria:
l participating caregivers were aged ≥ 18 years
l child was aged between 12 and 36 months
l child scored in the top 20% of population norms for behaviour problems on the parent-reported
Strengths and Difficulties Questionnaire (SDQ)
l written informed parental consent from participating caregivers.
Exclusion criteria
Participants were not eligible to participate if any of the following criteria were met:
l child or parent had severe sensory impairment, learning disability or language limitation that was
sufficient to preclude participation in the trial
l a sibling was already participating in the trial
l family was participating in active family court proceedings
l parent was participating in another closely related research trial and/or was receiving an individual
video-feedback-based intervention.
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Setting
Recruitment for the study was conducted in six UK NHS trusts: Central and North West London
NHS Foundation Trust, Whittington Health NHS Trust, Oxford Health NHS Foundation Trust, North
East London NHS Foundation Trust, Cambridgeshire and Peterborough NHS Foundation Trust, and
Hertfordshire Community NHS Trust. Recruitment efforts were predominantly targeted across seven
areas within these trusts: the London Boroughs of Camden, Hillingdon, Islington, and Barking and
Dagenham, as well as Oxfordshire, Peterborough and Hertfordshire. Research assessments were
carried out in participants’ homes or in another setting if the participant preferred (e.g. a private room
in a children’s centre).
Recruitment procedure
There were two stages of recruitment in the study. In stage 1, potential participants in participating
NHS sites were screened for behaviour difficulties using the parent-reported SDQ.42 The principal
pathway for recruitment was through health visiting services, with health visitors screening families
using a study screening pack during routine 12- and 24-month child health reviews. This was
supplemented by direct screening undertaken by members of the research team and CRN support
staff in the waiting room of these clinics and children’s centres. Health visiting services also posted
screening information to families with children within the target age range, and advertisements for the
study were placed in health visiting centres and GP surgeries. Participants were also recruited through
wider community services including nurseries, libraries, and through social media advertisements in local
and community forums. Recruitment advertisements included the questions ‘[I]s your child’s behaviour
sometimes a challenge?’ and ‘[A]re you interested in finding out more about your child’s behaviour?’.
In stage 2 of recruitment, the research team contacted caregivers by telephone if their children met
the eligibility criteria based on their scores on the SDQ questionnaire (i.e. scoring in the top 20% of
population norms). During this telephone call, the family’s full eligibility and interest in participating in
stage 2 of the study were assessed. Researchers also enquired as to whether or not there were two
parents/caregivers in the family and, if so, if both would be willing and available to participate in the
study. Interested participants were sent an information pack for stage 2 of the study by e-mail or post,
and a date to meet with them at their home for the baseline assessment visit was scheduled.
Informed consent
Participating parents/caregivers provided written informed consent for each stage of the study.
All participant resources were ethics approved [see www.journalslibrary.nihr.ac.uk/programmes/hta/
130433/#/documentation (accessed January 2021) for participant information sheets (PISs) and consent
forms used through both stages of the trial, as well as template letters used to inform GPs and
health visitors of families’ study participation]. In stage 1, potential participants were given screening
packs containing an information leaflet and the stage 1 PIS and consent form, alongside the screening
questionnaire. Parents/caregivers were able to provide written or electronic consent to complete
the screening stage of the study. Consent for stage 2 of the study was not provided at this point.
Participants who were eligible for and interested in the second stage of the study, the full RCT, were
sent the stage 2 PIS either by e-mail or by post following a telephone call from the research team
and ahead of their scheduled baseline assessment. The PIS and the clauses of the consent form were
then fully explained in person to participants by a trained researcher at the beginning of the research
assessment. Participants’ right to withdraw from the trial at any point was explained. Participants were
given the opportunity to ask any questions that they had.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
4
Baseline assessment
Baseline assessments were carried out in participants’ homes (or, in a very small number of cases,
in private rooms of children’s centres close to participants’ homes). At baseline, trained researchers
obtained written informed consent and collected family demographic information. Parent demographic
information included parents’ sex, age, ethnicity, education level, employment status and relationship
status. Child demographic data included children’s sex, age and ethnicity. Measures administered during
the baseline assessment can be seen in Table 1.
The baseline visits took between 2 and 2.5 hours to complete (depending on the number of caregivers
participating). All baseline assessments were conducted between July 2015 and July 2017.
Follow-up
Follow-up visits took place at two time points. The first was a post-treatment assessment (i.e. after the
VIPP-SD intervention for those in the treatment group), approximately 5 months post randomisation,
whereas the second was scheduled for 24 months post randomisation, when the children were aged
3–5 years. These assessment points were timed to allow for an initial post-intervention assessment
when treatment would have usually been completed (5-month assessment) and to assess for longer-
term outcomes (24 months). To assess whether or not the intervention had clinically significant
effects on child behaviour problems, the measures of child behaviour collected at baseline were
also administered at both follow-up visits. Similarly, measures of self-reported parenting practices,
as well as parent mental health measures, and couple functioning, where appropriate, were also
TABLE 1 Timing of data collection
Data Measure Source






Demographicsa Parents’ and children’s sex, age, and
ethnicity; parent education level,
employment status and relationship
status
Interview ✗ ✗
Primary outcome PPACS Interview ✗ ✗ ✗
Secondary outcomes CBCL Questionnaire ✗ ✗ ✗
SDQ (parent report) Questionnaire ✗ ✗ ✗
SDQ (teacher report) Questionnaire ✗
PHQ-9 Questionnaire ✗ ✗ ✗
GAD-7 Questionnaire ✗ ✗ ✗
Parenting Scale Questionnaire ✗ ✗ ✗
RDAS Questionnaire ✗ ✗ ✗
Economic data CA-SUS Interview ✗ ✗ ✗
Implementation data Participant feedback questionnairea,b Questionnaire ✗
Intervention fidelity Audio recordings ✗
CA-SUS, Child and Adolescent Service Use Schedule; CBCL, Child Behaviour Checklist; GAD-7, Generalised Anxiety
Disorder-7; PHQ-9, Patient Health Questionnaire-9; PPACS, Preschool Parental Account of Children’s Symptoms;
RDAS, Revised Dyadic Adjustment Scale.
a See www.journalslibrary.nihr.ac.uk/programmes/hta/130433/#/documentation (accessed January 2021).
b This measure was sent to and returned by participants by post.
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repeated at follow-up time points. Families were also asked to complete a structured interview of
service use at both follow-up time points to assess cost-effectiveness. Administration of all trial
measures is outlined in Table 1.
The follow-up visits took between 2 and 2.5 hours to complete. All follow-up data were collected
between December 2015 and July 2019. Figure 1 shows the Consolidated Standards of Reporting
Trials (CONSORT) flow diagram outlining participant recruitment and retention during the study.
Intervention
Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline is a manualised,
home-based intervention developed by Juffer, Bakermans-Kranenburg and van IJzendoorn and based
on attachment theory and social learning theory.18 The goal of the intervention is to promote parents’
sensitivity (i.e. their capacity to identify their child’s attachment cues and exploratory behaviour, and
respond to them appropriately), as well as sensitive discipline, which involves a consistent but non-
harsh response to challenging behaviour. VIPP-SD was delivered by trained therapists over six sessions,
lasting 1–2 hours, at approximately fortnightly intervals. The role of the therapist was to develop a
trusting and empathetic relationship with the parent(s) and to deliver the six sessions (four core
sessions and two booster sessions) in line with the manual.
The first half of each session involved the therapist filming the parent with their child during interactions
that aimed to reflect everyday situations, such as reading a book together, playing with toys and a
mealtime. Following the session, the therapist used the video-recorded interactions to write a feedback
script based on an appraisal of the parent’s interaction profile needs, the guidelines of the protocol, and
the sensitivity and discipline themes for that session. The parent and therapist spent the second half of
each session reviewing the interactions filmed in the previous visit, with the therapist frequently pausing
the video to deliver feedback based on the script they had prepared following the last session. The content
and focus of each session were manualised, but the feedback was delivered in an individualised way,
as feedback is unique to each parent and child in that moment. A modified version of VIPP-SD, Video-
feedback Intervention to promote Positive Parenting for Co-parents (VIPP-Co),43 was delivered when
two caregivers in the family were participating. The content and themes of the VIPP-Co intervention
broadly mirrored the VIPP-SD manual, with additional emphasis on interactions involving both caregivers
together with the child and on positive co-parenting. In the first three sessions, feedback was delivered
separately to each caregiver (as in VIPP-SD) and, from session 4 onwards, feedback was delivered to
both caregivers together. The intervention was delivered by 40 trained therapists, the majority of whom
were health visitors, community nursery nurses and clinical psychologists, as well as a small number of
professionals from other backgrounds, such as family and child therapy, psychology and psychiatry.
Fidelity
Each therapist delivering the intervention undertook 4 days of VIPP-SD training, as well as an additional
day of training on delivering the intervention to two caregivers and on the study protocol. Therapists
undertook supervised clinical practice with a practice case before becoming a therapist on the trial and
received regular clinical supervision throughout the trial. Therapists audio-recorded the feedback of
sessions and reported on fidelity in terms of the delivery of key components of the treatment, as well
as reporting on global adherence to the manual. We randomly selected 10% of audio-recordings to
allow two assessors trained in the intervention to rate the quality of sessions and adherence to the
VIPP-SD manual.
METHODS






• Child scored < 8 on externalising subscale, n = 1374
• Child out of age range, n = 12
• No consent to contact for phase 2, n = 14
• Child or parent had severe sensory impairment,
    learning disability or language limitation, n = 25
• Sibling participating in trial, n = 4
• Parent receiving video-feedback intervention, n = 1 
• Assessed at 2-year follow-up (n = 142; 94%)
    ° Primary outcome completed, n = 140
    ° Only secondary outcome(s) completed, n = 2
• Lost to 2-year follow-up (n = 9; 6%)
    ° Unresponsive to contact, n = 8
    ° Moved abroad, n = 1
• Assessed at 5-month follow-up (n = 140; 93%)
• Lost to 5-month follow-up (n = 11; 7%)
    ° Unwell/diff icult life circumstances, n = 4
    ° Declined (time), n = 2
    ° Could not be contacted, n = 3
    ° Moved abroad, n = 2 
Allocated to intervention
(n = 151)
• One caregiver participating, n = 125
• Two caregivers participating, n = 26
• Assessed at 5-month follow-up (n = 146; 98%)
• Lost to 5-month follow-up (n = 3; 2%)
    ° Could not be contacted, n = 2
    ° Moved abroad, n = 1  








Declined/could not be contacted
(n = 518)
• Unable or unresponsive to contact, n = 204
• Not interested in participating, n = 92
• Family member unwell/bereavement, n = 10
• For logistics reasons (99, time constraints; 18,
    outside catchment area; 6, treatment capacity did
    not match parents’ availability), n = 123
• Withdrew after baseline visit, n = 2
• Recruitment target reached before enrolment, n = 87
At least one caregiver
• Received 6 sessions, n = 121
• Received 5 sessions, n = 4
• Received 4 sessions, n = 4
• Received 3 sessions, n = 1
• Received 2 sessions, n = 3
• Received 1 session, n = 6
Did not receive allocated
intervention (n = 12)
• Assessed at 2-year follow-up (n = 144; 97%)
    ° Primary outcome completed, n = 142
    ° Only secondary outcome(s) completed, n = 2
• Lost to 2-year follow-up (n = 5; 3%)
    ° Unresponsive to contact, n = 3
    ° Child not in parental care, n = 1
    ° Declined (time), n = 1
Randomised
(n = 300)
• One caregiver participating, n = 124
• Two caregivers participating, n = 25
FIGURE 1 The CONSORT flow diagram for the Healthy Start, Happy Start RCT.
DOI: 10.3310/hta25290 Health Technology Assessment 2021 Vol. 25 No. 29
© 2021 O’Farrelly et al. This work was produced by O’Farrelly et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the
title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
7
Usual care
Participants in both groups continued to receive their usual care, which was minimal in most cases (there
are no standard care pathways in the NHS for early-onset behaviour problems). Some participants received
support and advice from a health visitor or GP, referral to early intervention mental health services linked
to a children’s centre, or parenting advice and support sessions. Data were collected on concurrent use of
health and social care services and are presented in Chapter 4.
Outcome measures
Primary outcome
The primary outcome for the trial was the assessment of the severity of behaviour problems at 5 months
post randomisation, measured using a modified version of the Preschool Parental Account of Children’s
Symptoms (PPACS)44,45 (see Appendix 1). The PPACS is a semistructured interview administered by
trained researchers and conducted with the child’s primary caregiver. Interview measures are considered
the gold standard outcome measure as they can circumvent potential biases related to parent-reported
outcomes.46 We made minor adaptations to the measure for use in the current study to ensure its
suitability for use with children in the sample’s age range.
During the PPACS interview, the primary caregiver is asked to recall and describe detailed examples of
their child’s typical behaviour over the past week in a range of settings (e.g. in the home, with friends,
in public). The objective of this approach is to allow the interviewer to rate the child’s behaviour based
on real examples, rather than caregivers’ global impressions or judgements of whether or not the
behaviour is normal. To ensure that the example given is characteristic of the child, caregivers are
asked how representative the described behaviour is of the child in the last 4 months. The researcher
rates the severity and frequency of the child’s symptoms based on professional judgement, following
training, guided by written definitions and thresholds of each of the scored behaviours. The interview
is used to score the children on two subscales; the first measures ADHD/hyperkinesis, whereas the
second measures conduct problems.
This measure has high inter-rater reliability and good construct validity, and has been used as an
outcome measure in a number of other clinical trials assessing intervention effects on child behaviour.47–49
Thirty interviews were randomly selected by the study statistician to be double-scored by another
trained researcher to ensure inter-rater reliability in the current study. One-way, single-measurement,
absolute agreement intraclass correlation coefficients were calculated for each time point and indicated
high levels of inter-rater reliability among researchers (with intraclass correlation coefficients as follows:
baseline – total score, 97; conduct subscale, 93; hyperactivity subscale, 97; 5-month follow-up – total
score, 96; conduct subscale, 95; hyperactivity subscale, 95; and 24-month follow-up – total, 92; conduct
subscale, 72; and hyperactivity subscale, 98).
Key secondary outcomes
Based on prespecified hypotheses in the trial protocol, there were two key secondary outcomes
measuring child behaviour.
Strengths and Difficulties Questionnaire
The SDQ42 was used to measure behaviour problems as it is routinely used in both research and
practice settings the UK. Participating caregivers were asked to complete this questionnaire. At the
24-month follow-up, the child’s nursery or school was also asked to complete the questionnaire, if
parental consent was given. The measure comprises 25 items that respondents rate on a three-point
scale (0 = not true, 1 = somewhat true or 2 = certainly true). The items are divided between five
subscales: emotional symptoms, conduct problems, hyperactivity/inattention, peer relationship problems
and prosocial behaviour. Scores on the conduct problems and hyperactivity scales can be combined to
METHODS
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provide an overall externalising behaviour score. The preschool version of the SDQ (for children aged
2–4 years) was used. The psychometric properties and utility of this version have been established in
children aged 2 and 3 years.50,51
Child Behaviour Checklist
Behaviour problems were also measured using the Child Behaviour Checklist (CBCL).52 The CBCL is a
100-item questionnaire that asks parents to rate how true the behaviour is of their child over the last
2 months on a three-point scale (0 = not true, 1 = somewhat true or 2 = very true or often true). The
measure gives a total score, an externalising score and an internalising score. The externalising score is
made up of two syndrome subscales for attention problems and aggressive behaviours. The internalising
score is made up of items from the emotionally reactive, anxious/depressed, somatic complaints and
withdrawn syndrome subscales. The CBCL was selected for use as well as the SDQ because it has been
validated in children as young as aged 12 months and is widely used in research studies.53
Other secondary outcomes
Parenting scale
Parenting practices were assessed using the self-reported Parenting Scale,54 which is a measure of
dysfunctional discipline practices in parents. The Parenting Scale is a 30-item questionnaire that asks
parents to rate how they would respond to various behaviour problems, with each item receiving a
score of 1–7 (effective to ineffective strategies).
Patient Health Questionnaire-9
Self-reported depression severity and symptomatology were measured using the Patient Health
Questionnaire-9 (PHQ-9).55 The PHQ-9 is a nine-item questionnaire, with each statement corresponding
to one of the nine criteria for depression outlined in the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV).56 Each statement is scored for the frequency in which the parent has
experienced each problem over the last 2 weeks. Scores range from 0 (not at all) to 3 (nearly every day),
with a total score obtained by summing all items of the questionnaire.
Generalised Anxiety Disorder-7
Parental anxiety was assessed using the Generalised Anxiety Disorder-7 (GAD-7).57 The GAD-7 is a
seven-item questionnaire that asks respondents how often they have experienced each problem in the
last 2 weeks. Each statement is scored from 0 (not at all) to 3 (nearly every day), with a total score
obtained by summing all items of the questionnaire.
Revised Dyadic Adjustment Scale
Relationship adjustment was measured using the Revised Dyadic Adjustment Scale (RDAS).58 The RDAS
is a 14-item questionnaire consisting of three subscales: dyadic consensus, dyadic satisfaction and dyadic
cohesion. Scores range from 0 to 69, where higher scores indicate greater relationship satisfaction and
lower scores suggest greater relationship distress.
Child and Adolescent Service-Use Schedule
Information on the use of health and social care services was recorded in an interview using a modified
version of the Child and Adolescent Service Use Schedule (CA-SUS).59 Modifications to the CA-SUS
were based on a review of recent literature and clinical feedback. This is an interview measure
conducted with the child’s primary caregiver that asks parents to recall use (number and duration of
appointments/sessions) of key services. Data were collected on the use of accommodation services
(e.g. foster care, supported housing), hospital services (e.g. inpatient stays, outpatient contacts, accident
and emergency attendances), community-based health and social care services (e.g. contacts with GPs,
clinical psychologists) and all prescribed medication. Parents/caregivers were interviewed at baseline
and asked about their child’s use of services and/or their use of services in relation to their child’s
needs in the previous 3 months. At subsequent follow-up points (5 and 24 months), service use was
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recorded for the period since the previous interview to ensure that the entire duration of the trial had
been captured.
Feedback questionnaire
Parents who were allocated to the intervention group were also asked to complete a feedback
questionnaire [see www.journalslibrary.nihr.ac.uk/programmes/hta/130433/#/documentation (accessed
January 2021)] following the 5-month follow-up assessment visit to explore their satisfaction with
and experiences of the VIPP-SD programme. The questions were related to their perceived impact of
the programme (in terms of their relationship with their child and their child’s communication and
behaviour) and their satisfaction with the home-based delivery format.
Serious adverse events
Serious adverse events (SAEs) were defined as ‘an adverse event that results in death, is life-
threatening, requires hospitalisation or prolongation of existing inpatient’s hospitalisation, results
in persistent or significant disability or incapacity’ [reproduced with permission from the European
Medicines Association. Guideline for Good Clinical Practice E6(R2)60]. The occurrence of SAEs was collected
at the 5- and 24-month follow-up assessments. Child hospitalisation data were collected using the
CA-SUS. Owing to the low-risk nature of this trial, non-serious adverse events were not collected.
Sample size
A sample size of 300 children and their caregiver/parent(s) was selected to provide between 80% and
90% power to detect standardised effect sizes of 0.36 and 0.42, respectively, on the primary outcome,
at a 5% level of statistical significance, and assuming a 20% attrition rate. The analysis was adjusted
for baseline behaviour score, time from randomisation to follow-up, recruitment site, age of child at
recruitment, and caregiver involvement (one vs. two participating caregivers) as fixed effects. This is
likely to have increased power to > 90% as such adjustment, especially for baseline scores of the same
variable, will have reduced the residual error variance in our model.
Randomisation and blinding
The randomisation list was prepared by an independent statistician using block sizes of two, four and
six (varying at random) and 1 : 1 allocation to either VIPP-SD or usual care. The randomisation list was
uploaded to the study electronic data capture system before the trial commenced. Randomisation was
performed using a web-based randomisation system linked to the trial database following enrolment by
the researcher who conducted the baseline assessment and who was blind to all treatment allocations.
Eligible participants were allocated online to the next available treatment code in the appropriate
stratum. Randomisation was stratified by recruitment site and the number of caregivers participating
(one vs. two). Access to the allocation sequence was restricted to an independent statistician and
appropriate members of the InForm™ (version 4.6) technical support team (Imperial College London,
London, UK) to maintain allocation concealment.
Following randomisation, the trial manager informed participants of their allocated groups and matched
participants to therapists for treatment according to the availability of both the therapists and the
parents. All assessors remained blind to treatment allocation for the duration of the study. Participants
were reminded of the importance of researchers remaining blinded to group allocation by the trial
manager or administrative assistant at each contact when scheduling their follow-up assessments.
Researchers also reminded parents of the importance of blinding in person at the start of the follow-up
visits to ensure that researchers stayed blinded to group allocation during the assessment. In cases
where unblinding did occur, the primary outcome (PPACS) was re-scored by a blinded trained assessor.
METHODS
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Data collection and data management
The trial’s source data included paper forms, questionnaires, written interview notes, scoring from
researchers’ research assessments, and feedback notes and log books from trial therapists’ intervention
sessions. Source data were collected and stored securely in accordance with the International Council
for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
(ICH) good clinical practice (GCP),61 the Data Protection Act62 and the UK Policy Framework for Health
and Social Care Research.41 Following the assessments/intervention visits, data were entered on an
electronic Case Report Form (eCRF) developed in InForm™, an electronic data capture system built
around an Oracle database. The InForm system includes automated range checks and validation rules
for data entry to help ensure data accuracy. A computer-generated audit trail is in place that records
the date, time, operator, operation and previous value of all manipulation of clinical data.
InForm storage and management were undertaken by the Imperial College Information and
Communication Technologies (ICT) team. InForm sits on a server behind a firewall connected to the
College Storage Area Network (SAN). The data are backed up regularly to removable media, which
allows for disaster recovery. In addition to the College backup facility, every 20 minutes, the activity
logs for the trial are moved to another server in a different location to facilitate rapid recovery of data
should it become necessary (e.g. in a disaster recovery scenario). Access to the system was restricted
to trained staff with unique password-protected accounts. Identifiable data were not recorded in the
eCRF and participants were identified by a unique trial identifier only.
All data monitoring and cleaning were also completed on InForm. Predefined data ranges were included
in the eCRF, which raised automated queries if data outside the expected range were entered. In addition
to the automated queries, the trial data were reviewed on a regular basis by the trial manager and
trial statistician for discrepancies and errors. Data cleaning was performed prior to each Data Monitoring
and Ethics Committee (DMEC) meeting and prior to database lock. Final data checks were performed by
the statistician once the database had been soft locked and before hard lock was complete. All outstanding
queries were resolved prior to the database hard lock.
Quality assurance and monitoring
Quality assurance (QA) and monitoring were performed in accordance with ICTU standard operating
procedures (SOPs). A risk assessment was conducted by the ICTU QA manager prior to the start
of the study, which assigned a risk category of ‘low risk’ to the trial. A monitoring plan was developed
in accordance with the risk assessment to define how monitoring procedures would be carried out and
the level of source data verification required for the study.
In accordance with the monitoring plan, 100% of participant consent forms and SAEs were source-
verified. Further to this, 20% of key trial data were also source-verified against the original paper
records, which included the primary outcome (PPACS); two of the secondary outcomes (i.e. CBCL and
SDQ); and 10% of demographics, therapist logbooks and all other outcomes (Parenting Scale, PHQ-9,
GAD-7, RDAS and CA-SUS).
Discrepancies noted between the paper records and trial database were queried and corrected in
the trial database. Monitoring was carried out centrally by the research team, ensuring that the
member of staff carrying out source data verification was not the same person who had performed
data entry in each case. Participant data to be monitored were identified by the trial statistician
through random selection.
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Data analysis
A comprehensive statistical analysis plan was produced before undertaking the analysis and agreed
with the Project Management Group (PMG), Trial Steering Committee (TSC) and DMEC. Primary
analyses were conducted on an intention to treat (ITT) basis.
Multiple linear regression was used to assess the primary outcome measure, the difference in PPACS
score between the trial groups at 5 and 24 months post randomisation. The PPACS score at the
5-month follow-up was the dependent variable, whereas trial group, PPACS score at baseline, time
since randomisation, recruitment centre, age of the child at recruitment and number of parents/
caregivers participating (one or two) were included as independent variables. Separate models were
fitted at 24 months (adjusting for the baseline measurements, but not the 5-month measurements).
These were distinct from the models fitted at 5 months (which, again, were adjusted for baseline
measurements). Similar models, with adjustment for the appropriate baseline score, were used to
assess the difference in CBCL and SDQ scores between the trial groups at the 5-month follow-up.
Regression residuals were plotted to assess their fit to the normal distribution using probability plots.
PPACS scores (total and subscales) were normally distributed at 5 months and close to normal at
24 months. Inspection of residuals plots suggested assumption of homoscedasticity and of linearity were
also reasonably well met. Visual inspection of the residuals from the regression analyses of secondary
outcomes at 5 and 24 months suggested that they were close to normally distributed. Repeating
the regression models using bootstrap methods (that allow for departure from normality) produced
very similar results. For consistency, the results based on linear regression only are presented.
Secondary outcomes that were completed by each participating caregiver were analysed separately by
sex. Standardised effect sizes (also known as d) were calculated by dividing the differences in means by
the standard deviation in the usual-care group at follow-up.
Missing answers to individual questions in the PPACS were imputed. Unrateable or missing items in
the attention/hyperactivity scale occurred most often when children did not regularly undertake an
activity required for scoring (e.g. watching television or playing with a sibling/friend on the same
activity). This assumption of ‘missing at random’ inherent in the multiple imputation analysis seems
reasonable here. This implies assessing attention based on the activities that the child regularly
undertakes (e.g. playing alone and eating a meal), by imputing values for activities that the child
does not regularly undertake (e.g. watching television and/or playing with a friend or sibling). There
were negligible missing data in the conduct disorder scale. The level, pattern and likely causes of any
missingness in the baseline variables and primary outcome were investigated. Multiple imputation
was of individual missing items in the PPACS interview when it was partially completed (because
this always implied that at least 50% of items in the scale had been completed). Multiple imputation
of the whole score was performed if the entire scale was missing. At the 5- and 24-month follow-ups,
imputation was based on randomised group, sex of child, age of child at the 5- and 24-month assessments
and baseline score, utilising information from both the baseline and 5- and 24-month PPACS interviews.
Imputation at baseline was based on randomised group, sex of child, age of child at baseline and
information from the baseline PPACS questionnaire.
Missing items in the other secondary outcome scales (child behaviour as assessed by the CBCL and
SDQ; and self-reported parental discipline behaviour, mood, anxiety and couple functioning) were dealt
with by scaling up. Thus, the sum of the maximum possible scores for non-missing items in each scale
was divided by the maximum possible total score for a fully completed scale to give the proportion of
the scale that had been completed (inflation factor). Scaling up was achieved by dividing the observed
total score for each scale by the inflation factor. The proportion of missing items was generally
negligible. See Appendix 2 for additional information on multiple imputation.
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Analysis of the primary outcome was repeated without adjustment for time since randomisation and
using complete cases after multiple imputation of missing items only. Analysis was also repeated
assuming that those who did not have PPACS follow-up data available had better than anticipated
results and then worse than anticipated results (anticipated by multiple imputation, better and worse by
one standard deviation of the difference between PPACS scores at follow-up and at baseline). In further
analyses, unrateable items within PPACS were filled in as the best possible scores and then as the worst
possible scores. Analysis of primary and secondary child behaviour outcomes was repeated for each
domain separately. Complier-average causal effects (CACE) analysis was performed, using two-stage
least squares regression analysis, to determine the effect of receiving the intervention, rather than just
being randomised to receive it. Compliance was defined as receipt of the four core VIPP-SD visits.
Planned subgroup analyses of the primary outcome were of the effects of child age at baseline
(12–23 months compared with 24–36 months) and of the number of parents participating (one vs.
two). We also undertook an ad hoc subgroup analysis to assess the effect of quartiles of severity of
child behaviour problems at baseline and of fidelity of the intervention in those randomised to VIPP-SD.
The magnitude of the treatment effect was estimated by repeating analysis of the primary outcome
for each subgroup separately (and for each fidelity group compared with all patients allocated to the
usual-care group).
All analyses were conducted using Stata® (StataCorp LP, College Station, TX, USA) software
(versions 13.0 and 15.0).
Trial organisation and management
Trial management
The trial was managed by the UK Clinical Research Collaboration registered ICTU, including statistics,
operations, database development and QA. The trial manager was based with the chief investigator at
the Division of Psychiatry in Imperial College London, working in collaboration with the ICTU.
The trial was overseen by three main oversight committees: (1) TSC, (2) PMG and (3) DMEC. A patient
and public involvement (PPI) group was also convened.
Trial Steering Committee
The TSC provided overall supervision of the trial, monitoring the progress of the study, ensuring
that there were no major protocol deviations and providing advice to the trial investigators. The TSC
comprised an independent chairperson, two members of the PPI group and, in general, four additional
independent members, as well as non-independent members, including the chief investigator, the trial
and operations managers and the senior study statistician. Membership of the TSC was approved
by the NIHR Health Technology Assessment (HTA) programme prior to convening the committee.
The TSC met prior to the commencement of the study, every 6 months during recruitment (2015–17)
and annually during follow-up. The TSC agreed on a charter, in line with NIHR guidelines,63 outlining its
responsibilities at the first meeting.
Project Management Group
The PMG was responsible for overseeing the management of the study and operational issues. The
PMG met every 2 months during the set-up phase of the trial and quarterly thereafter. Members
of the PMG included the chief investigator, investigators, the trial and operations managers, and the
trial statistician.
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Data Monitoring and Ethics Committee
The independent DMEC was responsible for overseeing the safety and data quality of the trial and met
annually during the trial. The committee monitored and reviewed trial recruitment, adherence to the
protocol, SAEs and interim outcome data presented by the trial statisticians. The NIHR HTA programme
approved and invited all members of the committee. The DMEC agreed on a charter outlining its roles
and responsibilities at the first meeting. The charter was prepared in line with the Data Monitoring
Committees: Lessons, Ethics, Statistics (DAMOCLES) charter64 and NIHR guidelines.63
Patient and public involvement group
Our PPI group was composed of seven representatives and included members of the pilot study, as
well as those identified through community and health-care services. Group members were mothers
and fathers of young children and/or educational/child care professionals. The PPI group contributed
to the study’s progress throughout the trial and provided significant and important input on the design
and management of the study. The group met annually from the start of the trial in 2015 until the end
of the trial in 2019, with an average of four members attending each meeting.
Public involvement was a key element in the study’s success, with the PPI group providing ideas,
advice and feedback that were integral to the study’s recruitment processes, participant retention, data
collection procedures and dissemination of study findings. Specifically, the group was able to advise
and offer feedback on the optimal settings and services needed to be targeted for trial recruitment,
especially for populations, such as fathers, that previous studies have often struggled to engage
and accommodate. The PPI group also helped to produce and develop a brief, informative video for
use in recruitment purposes. The video outlined what participation in the trial would involve and was
provided to families alongside the PIS. A study within a trial (SWAT) aimed to explore whether or not
the addition of this video aided the consent process.
A key study success was sustaining high levels of participant retention across the 2-year follow-up
period (95% and 94% retention at the 5- and 24-month follow-ups, respectively). The PPI group
was, again, integral to this process and advised on the key engagement strategies implemented by the
study team. These included the creation of a study website for caregivers to visit, a welcome pack
for families, the use of certificates and visit trackers for the children following each assessment, the
sending of birthday cards to the children, a thank-you toy to acknowledge children’s participation,
and the sharing of sample clips from the visits as a keepsake. Regular newsletters sent to participating
families by e-mail were also a key initiative of the PPI process. The newsletters provided an update on
the study, informed participants about what was coming next and constituted a pathway for families to
easily update the study team with any changes in contact details. This meant that the study team was
able to communicate more efficiently and effectively with families when it came to arranging follow-up
assessments. The PPI group was also involved in decisions around how to communicate and explain the
study findings to participants. The group recommended considering a range of different dissemination
materials, including an animation, a brief newsletter, an infographic, and an example story to illustrate
the study and its outcomes in a more personal way.
The PPI members were highly engaged and motivated throughout the project. At the start of each
meeting, a study summary was provided, as well as a recap on how the group’s suggestions and
feedback (from the previous meeting) had been implemented in the wider project. Two members of
the PPI group were also full members of the TSC and participated in the piloting of baseline and
follow-up assessments. All PPI members were reimbursed for incurred travel expenses and were
offered a voucher following each meeting in keeping with the INVOLVE guidelines.
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Amendments to protocol
l We changed the eligibility criteria so that participants who had previously received individualised
video-feedback programmes were no longer excluded. We also extended the eligibility criteria
to exclude parents who had a sensory impairment or learning disability that precluded their
participation in the trial.
l Timing of the primary outcome was extended from 4 to 5 months post randomisation because of
scheduling difficulties in completing the treatment in the allocated time for the intervention group
of the trial. This was to reduce the likelihood of systematic differences in the timing of the follow-up
assessments between the trial groups.
l Reporting of outcomes in the current report is confined to those that were funded as part of this
project and were included in the prespecified statistical analysis plan. Following an ethics amendment,
we amended the protocol to include one secondary and five exploratory outcomes. As a secondary
outcome, parent–child interaction data were collected across all three time points to allow for the
measurement of parental sensitivity, which was a target of the intervention. This measure may be
instructive in better understanding the mechanisms of this intervention. Exploratory outcomes were
also added at the 24-month time point. These measures included direct assessment of children’s
executive functions, emotion regulation, delay of gratification and narrative representations during
dolls house play, as well as genetic variance (through buccal swabs) and parental involvement.
Analyses of these variables is yet to be undertaken and findings will be published once available.
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Chapter 3 Clinical results
Participant flow and retention
Between 30 July 2015 and 26 July 2017, a total of 2248 families were assessed for eligibility. Of these
families, 1430 were ineligible, 518 did not progress to the trial (declined/could not be contacted) and
300 were randomised to stage 2 of the trial. In total, 151 participants (50%) were randomly allocated to
the VIPP-SD group and 149 participants (50%) to the usual-care group. We recruited to target (n = 300;
see Appendix 3 for the study’s recruitment graph), with the majority of participants recruited from
health visiting services (30% face to face and 25% through posting screening information to families with
children in the target age range) and children’s centres (30%). The remaining participants were recruited
largely from other community venues and online adverts (Table 2 shows a full outline of recruitment
pathways). Participants were recruited across seven NHS sites (Table 3). Follow-up data were collected
between December 2015 and July 2019. Follow-up data were analysed for 286 (VIPP-SD, n = 140;
usual care, n = 146) participants and 282 (VIPP-SD, n = 140; usual care, n = 142) participants at 5 and
24 months, respectively. See Figure 1 for the CONSORT flow diagram summarising the eligibility, trial
group allocation and subsequent progress of randomised participants. Approximately one-third of children
who were screened were eligible to take part in the study, which was higher than the anticipated 20%.
It is possible that families with children with elevated problems self-selected into the study and/or that
health visitors were more likely to complete screening with families who they thought may be more likely
to be eligible based on the child’s behaviour.
Baseline participant characteristics
Participant characteristics at baseline were well balanced between groups. Table 4 shows the baseline
characteristics of participating children and primary caregivers. The participating children had a mean
age of 23 months [standard deviation (SD) 6.7 months]; 54% were male and 65% were recorded as
being of white ethnicity. Participating primary caregivers were predominantly female (96%), with a
mean age of 34.2 years (SD 5.8 years). Most primary caregivers were married or cohabiting (85%),
were of white ethnicity (72%), had a graduate-level qualification (64%) and were in some form of
employment or on paid parental leave (59%). There were more male children in the usual-care group
(58%) than in the VIPP-SD group (50%), and the usual-care group was also more diverse in terms of
primary caregiver and children’s ethnicity. Appendix 4, Table 24, shows the baseline characteristics of
participating secondary caregivers.
TABLE 2 Route of recruitment for families randomised into the trial
Recruitment route at screening
Trial group, n (%)
VIPP-SD (N= 151) Usual care (N= 149) All (N= 300)
Routine developmental review/clinic by health visitors 47 (31) 44 (30) 91 (30)
Health visiting service posting screening information 34 (23) 40 (27) 74 (25)
Children’s centre 46 (30) 45 (30) 91 (30)
Other clinic/community venues 12 (8) 11 (7) 23 (8)
Online advert 9 (6) 5 (3) 14 (5)
Word of mouth 1 (1) 2 (1) 3 (1)
Other 2 (1) 2 (1) 4 (1)
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TABLE 3 Participants recruited into the trial disaggregated by recruitment site
Recruitment site Family recruited into RCT, n (%)
Family had two participating
caregivers, n (%)
Barking and Dagenham 14 (5) 1 (2)
Camden 83 (28) 13 (25)
Hertfordshire 7 (2) 0 (0)
Hillingdon 22 (7) 5 (10)
Islington 105 (35) 23 (45)
Oxford 43 (14) 5 (10)
Peterborough 26 (9) 4 (8)
Total 300 (100) 51 (100)
TABLE 4 Baseline characteristics of participating children and primary caregivers by treatment allocation
Characteristic
Trial group
VIPP-SD (N= 151) Usual care (N= 149) All (N= 300)
Child characteristic
Sex (male), n (%) 76 (50) 87 (58) 163 (54)
Age (months), mean (SD) 22.8 (6.8) 23.2 (6.5) 23 (6.7)
Ethnicity, n (%)
Asian 9 (6) 8 (5) 17 (6)
Black 3 (2) 15 (10) 18 (6)
Mixed ethnicity 36 (24) 25 (17) 61 (20)
White 100 (66) 94 (63) 194 (65)
Other 3 (2) 7 (5) 10 (3)
Primary caregiver characteristic
Sex (male), n (%) 8 (5) 5 (3) 13 (4)
Age (years), mean (SD) 33.7 (5.6) 34.7 (5.9) 34.2 (5.8)
Parental status, n (%)
Parent (including step or adoptive) 151 (100) 149 (100) 300 (100)
Ethnicity, n (%)
Asian 15 (10) 16 (11) 31 (10)
Black 3 (2) 15 (10) 18 (6)
Mixed ethnicity 11 (7) 11 (7) 22 (7)
White 114 (75) 103 (69) 217 (72)
Other 8 (5) 4 (3) 12 (4)
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Forty trained therapists delivered any amount of VIPP-SD (median three participants each; range
1–12 participants each). Therapists had a mean of 13 years’ experience (SD 12 years’ experience)
post-training in NHS services. Table 5 shows a full overview of therapist professions.
TABLE 4 Baseline characteristics of participating children and primary caregivers by treatment allocation (continued )
Characteristic
Trial group
VIPP-SD (N= 151) Usual care (N= 149) All (N= 300)
Relationship status, n (%)
Married/civil partnership/cohabiting 128 (85) 127 (85) 255 (85)
Divorced/widowed/legally separated 1 (1) 4 (3) 5 (2)
Single and none of the above 12 (8) 17 (11) 29 (10)
In a relationship but not cohabiting 10 (7) 1 (1) 11 (4)
Employment status, n (%)
Employed 66 (44) 64 (43) 130 (43)
Paid parental leave 6 (4) 10 (7) 16 (5)
Self-employed 20 (13) 12 (8) 32 (11)
Full-time student 3 (2) 7 (5) 10 (3)
Looking after home and children 56 (37) 56 (38) 112 (37)
Highest qualification, n (%)
GCSE or lower 17 (11) 14 (9) 31 (10)
A level/NVQ/BTEC 42 (28) 36 (24) 78 (26)
Graduate 92 (61) 99 (66) 191 (64)
A level, Advanced level; BTEC, Business and Technology Education Council; GCSE, General Certificate of Secondary
Education; NVQ, National Vocational Qualification.
TABLE 5 Professional backgrounds of therapists implementing VIPP-SD
Profession/training background n (%)
Health visitor 10 (25)
Community nursery nurse 8 (20)
Clinical psychologist 7 (17)
Trainee clinical psychologist 4 (10)
Researcher 4 (10)
Psychotherapist 3 (8)
Research nurse 2 (5)
Psychiatrist 2 (5)
Total 40 (100)
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Intervention dosage
Of the 151 participants randomised to the VIPP-SD group, 129 participants (85%) completed at least
four sessions (the compliance cut-off point for treatment adherence), with 121 of these participants
(80%) receiving all six sessions. Twelve participants (8%) received no intervention, with a further
10 participants (7%) completing one, two or three visits only.
Intervention fidelity
Treatment fidelity was assessed against the VIPP-SD manual and was found to be acceptable in the
majority of the sessions.18 Two assessors trained in the intervention rated audio-recordings using a
global scale of adherence to the manual on a five-point scale (1 = did not follow the manual at all;
2 = adapted most of the material, did not follow the manual closely; 3 = sometimes adapted the
material, followed manual somewhat; 4 = adapted only minor elements, followed the manual quite
closely; and 5 = followed the manual very closely and delivered the session as specified). A score
of 3 was set as the acceptable fidelity threshold as to receive this score most core components of
the intervention needed to be identified as present in the feedback. Following piloting of the scale, the
assessors double-scored a subset of 10 sessions (comprising 31 scripts) and established an acceptable
level of reliability [intraclass correlation coefficient (ICC) 0.69]. The fidelity assessment determined
that 94% (72/77 randomly selected audio-recordings of therapy sessions) met the minimum threshold
(score of ≥ 3) of adherence to the manual. The mean sum score of adherence across sessions was
3.66 (SD 0.60, range 3.4–4.0).
Primary outcome: Preschool Parental Account of Children’s Symptoms
score at the 5- and 24-month follow-ups
We present the primary outcome (total PPACS score) and its subscale scores at the 5-month (primary
time point) and 24-month follow-ups in Table 6. The group mean difference in PPACS score was
modelled using linear regression adjusted for baseline scores, treatment centre, randomised group,
length of follow-up, age of the child and the number of participating caregivers. At the post-treatment
5-month follow-up, the mean scores of child behaviour problems on the PPACS were found to have
decreased from 33.5 (SD 9.0) to 28.8 (SD 9.2) in the VIPP-SD group and from 32.4 (SD 10.6) to 30.3
(SD 9.9) in the usual-care group. This represents a significant difference in reduction of problems
favouring the VIPP-SD group [adjusted mean difference, VIPP-SD vs. usual care 2.03, 95% confidence
interval (CI) 0.06 to 4.01; p = 0.04]. The adjusted standardised effect size was Cohen’s d = 0.20 (95% CI
0.01 to 0.40). VIPP-SD was also found to be superior to usual care, in particular, on the conduct problems
subscale of the primary outcome [adjusted mean difference 1.61, 95% CI 0.44 to 2.78; p = 0.007 (d = 0.30,
95% CI 0.08 to 0.51)], but not the hyperactivity subscale [adjusted mean difference 0.29, 95% CI
–1.06 to 1.65; p = 0.67 (d = 0.05, 95% CI –0.17 to 0.27)].
At the 24-month follow-up, the adjusted mean difference on the total PPACS score remained about
the same, with a decrease in effect size of d = 0.03 [VIPP-SD vs. usual care 1.73, 95% CI –0.24 to 3.71;
p = 0.08 (d= 0.17, 95% CI –0.02 to 0.37)]. The adjusted mean difference on the conduct subscale continued
to favour the VIPP-SD group [VIPP-SD vs. usual care 1.07, 95% CI –0.06 to 2.2; p = 0.06 (d = 0.20,
95% CI –0.01 to 0.42)]. There was no evidence of the superiority of VIPP-SD over usual care on the
hyperactivity subscale [difference 0.62, 95% CI –0.60 to 1.84; p = 0.32 (d = 0.10, 95% CI –0.10 to 0.30)].
The positive effect of VIPP-SD on the PPACS total score at the 5-month follow-up was robust to
sensitivity analyses, which estimated the impact of varying the assumptions made in respect of missing
data and adjustment for length of follow-up (see Appendix 5, Table 28). Figures 2 and 3 present the forest
plots for the sensitivity analyses of the 5-month and 24-month follow-up PPACS scores, respectively.
Appendix 5 details the profiles of families with and without missing PPACS data (see Appendix 5, Table 29)
and reports descriptive outcome data for those with and without PPACS scores at the 5- and 24-month
follow-ups (see Appendix 5, Table 30).
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TABLE 6 Primary ITT analysis of adjusted mean difference on the primary outcome of children’s behaviour problems at




(95% CI) Effect sizeb (95% CI) p-value
VIPP-SD Usual care
n Mean (SD) n Mean (SD)
PPACSc total score – primary analysis at 5 months
Baseline 151 33.5 (9.0) 149 32.4 (10.6)
5 months 140 28.8 (9.2) 146 30.3 (9.9) 2.03 (0.06 to 4.01) 0.20 (0.01 to 0.40) 0.04
24 months 140 23.1 (8.2) 142 24.7 (9.9) 1.73 (–0.24 to 3.71) 0.17 (–0.02 to 0.37) 0.08
PPACSc conduct scale
Baseline 151 16.0 (5.8) 149 15.5 (6.4)
5 months 140 14.8 (5.1) 146 15.8 (5.4) 1.61 (0.44 to 2.78) 0.30 (0.08 to 0.51) 0.007
24 months 140 13.4 (4.8) 142 14.4 (5.3) 1.07 (–0.06 to 2.2) 0.20 (–0.01 to 0.42) 0.06
PPACSc ADHD scale
Baseline 151 17.5 (5.8) 149 16.9 (6.6)
5 months 140 14.0 (6.1) 146 14.5 (6.2) 0.29 (–1.06 to 1.65) 0.05 (–0.17 to 0.27) 0.67
24 months 140 9.7 (5.1) 142 10.3 (6.1) 0.62 (–0.60 to 1.84) 0.10 (–0.10 to 0.30) 0.32
a Difference in mean is the difference between treatment groups from linear regression analysis of the outcome
measure on the baseline score of that same measurement, on treatment centre, randomised group, length of
follow-up, age of the child and on the number of caregivers participating (all treated as fixed effects). Multiple
imputation was used for any unratable items in PPACS and also for anyone without PPACS assessment at follow-up.
Positive differences represent greater adjusted decreases in symptoms in the VIPP-SD group than in the usual-
care group.
b Effect size is the standardised difference in mean (adjusted as above). This is the difference in mean divided by the
SD of controls at follow-up.




As primary, but not adj f/u (as in SAP version 1.0)
Estimate (95% CI)
2.03 (0.06 to 4.01)
2.02 (0.24 to 3.80)
2.09 (0.13 to 4.06)
2.08 (0.31 to 3.86)
2.42 (0.43 to 4.42)
2.33 (0.53 to 4.13)
1.94 (−0.06 to 3.94)
1.95 (0.15 to 3.74)
2.13 (0.14 to 4.12)
2.10 (0.30 to 3.90)
2.56 (0.62 to 4.50)
2.48 (0.73 to 4.23)
1.86 (−0.08 to 3.80)
1.94 (0.18 to 3.69)
Difference in mean PPACS score at 5 months by treatment group, adjusted
Complete-case analysis
Complete case, not adj for f/u
Assuming no f/u implies better than MI outcomes
Assuming no f/u implies better than MI outcomes, not adj f/u
Assuming no f/u implies worse than MI outcomes
Assuming no f/u implies worse than MI outcomes, not adj for f/u
Complete case as per draft SAP, except adj for f/u
Complete case as per draft SAP (which did not adjust for f/u)
Missing items within PPACS replaced with maximum
Missing items within PPACS replaced with maximum, not adj for f/u
Missing items within PPACS replaced with minimum
Missing items within PPACS replaced with minimum, not adj f/u
−1 0 1 2 3 4 5
FIGURE 2 Forest plot for sensitivity analysis at the 5-month follow-up. adj, adjusted; f/u, follow-up.
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The primary analyses included multiple imputation (MI) for unrateable items on the PPACS scales,
MI for PPACS total scores in those who did not complete their 5-month follow-up assessment and
adjustment for length of follow-up. Sensitivity analyses included lack of adjustment for length of
follow-up (combined with other assumptions). Complete-case analyses are then reported (using MI
solely for unrateable items on the PPACS scale and excluding those who did not complete their
5-month follow-up). Further analyses assume better PPACS scores and then worse PPACS scores
(than predicted by MI by one standard deviation of the mean change in PPACS scores between the
baseline and 5-month follow-up assessment) in those who did not complete their 5-month follow-up.
The final analyses assume that unrateable PPACS items were replaced with the highest possible
score and then the lowest possible score.
Sensitivity analyses were completed at the 24-month follow-up in the same way as in the 5-month
follow-up sensitivity analyses. This included lack of adjustment for length of follow-up (combined with
other assumptions). Complete-case analyses are then reported (using MI solely for unrateable items
on the PPACS scale and excluding those who did not complete their 24-month follow-up). Further
analyses assume better PPACS scores and then worse PPACS scores (than predicted by MI by one SD
of the mean change in PPACS scores between the baseline and 24-month follow-up assessment) in those
who did not complete their 24-month follow-up. The final analyses assume that unrateable PPACS items
were replaced with the highest possible score and then the lowest possible score.
Secondary outcomes: parent-reported measures of child behaviour at the
5- and 24-month follow-ups
On the key secondary outcomes, parent-reported questionnaire measures of children’s behaviour
(total scores of the CBCL and SDQ), the results indicate a positive direction of effect favouring the
VIPP-SD group at the 5-month follow-up, yet indicate little evidence of a sustained effect at the
24-month follow-up (Table 7). At the 5-month follow-up, the VIPP-SD group had lower CBCL scores
[adjusted mean difference 3.24, 95% CI –0.06 to 6.54; p = 0.05 (d = 0.15, 95% CI 0.00 to 0.31)] and
Sensitivity analysis Estimate (95% CI)
Primary analysis
As primary, but not adj for f/u (as in SAP version 1.0)
Complete-case analysis
Complete case, not adj for f/u
Assuming no f/u implies better than MI outcomes
Assuming no f/u implies better than MI outcomes, not adj for f/u
Assuming no f/u implies worse than MI outcomes
Assuming no f/u implies worse than MI outcomes, not adj for f/u
Complete case as per draft SAP, except adj for f/u
Complete case as per draft SAP (which did not adjust for f/u)
Missing items within PPACS replaced with maximum
Missing items within PPACS replaced with maximum, not adj for f/u
Missing items within PPACS replaced with minimum
MIssing items within PPACS replaced with minimum, not adj for f/u
Difference in mean PPACS score at 24 months by treatment group, adjusted
–1 0 1 2 3 4 5
1.76 (−0.17 to 3.70)
1.69 (−0.26 to 3.64)
1.86 (−0.11 to 3.84)
1.84 (−0.16 to 3.83)
2.09 (0.10 to 4.08)
2.02 (0.01 to 4.04)
1.63 (−0.40 to 3.66)
1.58 (−0.47 to 3.63)
1.84 (−0.11 to 3.78)
1.77 (−0.19 to 3.73)
2.01 (0.05 to 3.97)
1.94 (−0.05 to 3.92)
1.80 (−0.16 to 3.75)
1.73 (−0.24 to 3.71)
FIGURE 3 Forest plot for sensitivity analysis at the 24-month follow-up. adj, adjusted; f/u, follow-up.
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SDQ scores [adjusted mean difference 0.93, 95% CI –0.03 to 1.90; p = 0.06 (d = 0.18, 95% CI –0.01 to
0.36)] than the usual-care group. At the 24-month follow-up, although the VIPP-SD group continued to
have lower behaviour scores than the usual-care group, these differences had diminished somewhat
and there was little evidence of sustained effects of VIPP-SD on the CBCL (adjusted mean difference
2.82, 95% CI –1.82 to 7.45; p = 0.23) and SDQ (adjusted mean difference 0.35, 95% CI –0.78 to 1.47;
p = 0.54). There was no evidence of superiority of VIPP-SD over usual care on the teacher-reported total
score for the SDQ at the 24-month follow-up (difference 0.54, 95% CI –1.00 to 2.08; p = 0.49).
Table 8 shows the adjusted group differences on the subscale scores for the secondary behaviour
outcomes (CBCL and SDQ) at the 5- and 24-month follow-ups. At the 5-month follow-up, there
was evidence of an effect favouring the VIPP-SD group over the usual-care group on the SDQ
externalising subscale [adjusted mean difference 0.68, 95% CI 0.00 to 1.37; p = 0.05 (d = 0.18, 95% CI
0.00 to 0.37)] as well as weaker evidence favouring the VIPP-SD group over the usual-care group on
the CBCL internalising scale [adjusted mean difference 1.03, 95% CI –0.10 to 2.16; p = 0.07 (d = 0.15,
95% CI –0.01 to 0.32)]. There was no strong evidence of group differences on the remaining subscales.
In general, differences on the subscales had attenuated at the 24-month follow-up and there was little
evidence of sustained effects on these measures. On the teacher-reported SDQ, although teachers
tend to report lower behaviour problems for the VIPP-SD group than for the usual-care group on key
subscales, there was only weak evidence of group differences on these subscales: conduct [adjusted
mean difference 0.38, 95% CI –0.16 to 0.92; p = 0.17 (d = 0.18, 95% CI –0.08 to 0.45)], hyperactivity
[adjusted mean difference 0.46, 95% CI –0.25 to 1.16; p = 0.20 (d = 0.17, 95% CI –0.09 to 0.43)]
and externalising [adjusted mean difference 0.81, 95% CI –0.29 to 1.92; p = 0.15 (d = 0.19, 95% CI
–0.07 to 0.45)] subscales.
TABLE 7 Primary ITT analysis of adjusted mean difference on secondary outcomes of children’s behaviour problems




(95% CI) Effect sizeb (95% CI) p-value
VIPP-SD Usual care
n Mean (SD) n Mean (SD)
CBCLc total score (primary caregiver report)
Baseline 151 40.7 (21.7) 149 42.7 (21.1)
5 months 140 32.5 (20.6) 145 37.2 (21.0) 3.24 (–0.06 to 6.54) 0.15 (0.00 to 0.31) 0.05
24 months 141 30.6 (23.4) 144 35.3 (23.7) 2.82 (–1.82 to 7.45) 0.12 (–0.08 to 0.31) 0.23
SDQc total score (primary caregiver report)
Baseline 150 13.8 (4.8) 149 14.0 (4.7)
5 months 140 11.3 (5.1) 145 12.2 (5.2) 0.93 (–0.03 to 1.9) 0.18 (–0.01 to 0.36) 0.06
24 months 141 10.4 (5.4) 144 10.9 (5.8) 0.35 (–0.78 to 1.47) 0.06 (–0.13 to 0.25) 0.54
SDQc,d total score (teacher report)
24 months 106 7.1 (6.0) 104 7.8 (5.7) 0.54 (–1.00 to 2.08) 0.10 (–0.18 to 0.37) 0.49
a Difference in mean is the difference between treatment groups from linear regression analysis of the outcome
measure on the baseline score of that same measurement, on treatment centre, on randomised group, on length
of follow-up, on age of child and on number of parents/caregivers participating (all treated as fixed effects).
Positive differences represent greater adjusted decreases in symptoms in the VIPP-SD group than in the
usual-care group.
b Effect size is the standardised difference in mean (adjusted as above). This is the difference in mean divided by the
SD of controls at follow-up.
c Higher scores represent higher levels of behaviour problems.
d Teacher-reported SDQ scores are adjusted for baseline primary caregiver-reported SDQ.
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TABLE 8 Intention-to-treat analysis of adjusted mean difference of change in children’s behaviour problems on the




(95% CI) Effect sizeb (95% CI) p-value
VIPP-SD Usual care
n Mean (SD) n Mean (SD)
CBCLc externalising subscale
Baseline 151 16.5 (8.1) 149 17.5 (8.3)
5 months 140 13.3 (8.3) 145 15.2 (8.5) 1.15 (–0.32 to 2.63) 0.14 (–0.04 to 0.31) 0.12
24 months 141 11.6 (8.8) 144 13.4 (9.6) 0.81 (–1.02 to 2.65) 0.09 (–0.11 to 0.28) 0.38
CBCLc internalising subscale
Baseline 151 8.9 (7.2) 149 9.7 (7.5)
5 months 140 7.1 (6.5) 145 8.5 (6.8) 1.03 (–0.10 to 2.16) 0.15 (–0.01 to 0.32) 0.07
24 months 141 8.1 (8.2) 144 9.0 (7.6) 0.44 (–1.16 to 2.04) 0.06 (–0.15 to 0.27) 0.59
CBCLc attention subscale
Baseline 151 3.8 (2.0) 149 4.2 (2.3)
5 months 140 2.9 (2.1) 145 3.5 (2.2) 0.25 (–0.18 to 0.68) 0.11 (–0.08 to 0.30) 0.26
24 months 141 2.2 (2.0) 144 2.7 (2.2) 0.27 (–0.18 to 0.71) 0.12 (–0.08 to 0.31) 0.24
CBCLc aggression subscale
Baseline 151 12.7 (6.9) 149 13.3 (7.0)
5 months 140 10.4 (6.8) 145 11.8 (6.9) 0.98 (–0.25 to 2.22) 0.14 (–0.04 to 0.32) 0.12
24 months 141 9.4 (7.4) 144 10.7 (7.9) 0.63 (–0.90 to 2.16) 0.08 (–0.11 to 0.27) 0.42
SDQd,e externalising subscale
Baseline 150 9.4 (3.0) 149 9.4 (3.5)
5 months 140 7.6 (3.4) 145 8.2 (3.7) 0.68 (0.00 to 1.37) 0.18 (0.00 to 0.37) 0.05
24 months 141 7.0 (3.6) 144 7.4 (4.1) 0.39 (–0.38 to 1.16) 0.10 (–0.09 to 0.29) 0.32
24 months
(teacher-report)
106 4.1 (4.2) 104 4.9 (4.3) 0.81 (–0.29 to 1.92) 0.19 (–0.07 to 0.45) 0.15
SDQd,e conduct subscale
Baseline 150 3.6 (2.0) 149 3.4 (2.1)
5 months 140 3.1 (1.9) 145 3.1 (2.0) 0.27 (–0.14 to 0.67) 0.13 (–0.07 to 0.33) 0.20
24 months 141 2.9 (2.0) 144 3.1 (2.3) 0.34 (–0.11 to 0.79) 0.15 (–0.05 to 0.35) 0.14
24 months
(teacher-report)
106 1.2 (2.0) 104 1.6 (2.1) 0.38 (–0.16 to 0.92) 0.18 (–0.08 to 0.45) 0.17
SDQd,e hyperactivity subscale
Baseline 150 5.9 (1.9) 149 6.1 (2.2)
5 months 140 4.5 (2.1) 145 5.1 (2.3) 0.37 (–0.08 to 0.81) 0.16 (–0.03 to 0.35) 0.11
24 months 141 4.1 (2.2) 144 4.3 (2.4) 0.07 (–0.40 to 0.53) 0.03 (–0.17 to 0.22) 0.78
24 months
(teacher-report)
106 2.9 (2.6) 104 3.4 (2.7) 0.46 (–0.25 to 1.16) 0.17 (–0.09 to 0.43) 0.20
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Table 9 shows the results of the secondary CACE analysis estimating the effects of receiving the
intervention (defined as at least four VIPP-SD sessions), rather than merely being randomised to it.
The CACE analysis was completed on the primary and secondary behaviour outcome measures
(PPACS, CBCL and SDQ). For the PPACS scores, the results showed a larger adjusted mean difference
favouring the VIPP-SD group at the 5-month follow-up when accounting for treatment adherence
[difference 2.59, 95% CI 0.24 to 4.94; p = 0.03 (d = 0.26, 95% CI 0.02 to 0.50)] than in the ITT analysis
[difference 2.03, 95% CI 0.06 to 4.01; p = 0.04 (d = 0.20, 95% CI 0.01 to 0.40)]. At the 24-month
follow-up, the difference remains in the same range, similar to the outcome in the ITT analysis,
although the adjusted group difference and effect size tends to be larger in the CACE analysis
[difference 1.96, 95% CI –0.30 to 4.23; p = 0.09 (d = 0.20, 95% CI –0.03 to 0.43)]. A similar pattern is
observed on the CBCL [adjusted mean difference 3.56, 95% CI 0.04 to 7.09; p = 0.05 (d = 0.17, 95% CI
0.00 to 0.34)] and SDQ [adjusted mean difference 1.03, 95% CI –0.01 to 2.06; p = 0.05 (d = 0.20,
95% CI 0.00 to 0.39)] at the 5-month follow-up, such that both outcomes show slightly larger adjusted
TABLE 8 Intention-to-treat analysis of adjusted mean difference of change in children’s behaviour problems on the




(95% CI) Effect sizeb (95% CI) p-value
VIPP-SD Usual care
n Mean (SD) n Mean (SD)
SDQd,e emotional problems subscale
Baseline 150 1.4 (1.5) 149 1.6 (1.5)
5 months 140 1.4 (1.7) 145 1.4 (1.5) 0.01 (–0.32 to 0.33) 0.01 (–0.21 to 0.22) 0.96
24 months 141 1.8 (1.8) 144 1.7 (1.8) –0.18 (–0.56 to 0.21) –0.10 (–0.30 to 0.11) 0.37
24 months
(teacher-report)
106 1.4 (1.8) 104 1.2 (1.7) –0.21 (–0.68 to 0.27) –0.12 (–0.40 to 0.16) 0.39
SDQd,e peer problems subscale
Baseline 150 3.0 (1.9) 149 3.0 (1.8)
5 months 140 2.3 (1.9) 145 2.5 (2.0) 0.23 (–0.19 to 0.64) 0.12 (–0.10 to 0.33) 0.29
24 months 141 1.6 (1.6) 144 1.8 (1.9) 0.15 (–0.24 to 0.53) 0.08 (–0.12 to 0.28) 0.44
24 months
(teacher-report)
106 1.6 (1.9) 104 1.6 (2.0) –0.06 (–0.59 to 0.47) –0.03 (–0.30 to 0.24) 0.82
SDQd,e prosocial scale
Baseline 150 5.7 (2.3) 149 5.4 (2.2)
5 months 140 6.6 (2.0) 145 6.3 (2.2) –0.07 (–0.47 to 0.34) –0.03 (–0.22 to 0.16) 0.75
24 months 141 7.7 (1.8) 144 7.3 (1.9) –0.19 (–0.59 to 0.21) –0.10 (–0.31 to 0.11) 0.36
24 months
(teacher-report)
106 7.1 (2.5) 104 6.7 (2.3) –0.31 (–0.94 to 0.33) –0.13 (–0.41 to 0.14) 0.34
a Difference in mean is the difference between treatment groups from linear regression analysis of the outcome
measure on the baseline score of that same measurement, on treatment centre, on randomised group, on length of
follow-up, on age of child and on number of parents/care-givers participating (all treated as fixed effects). Positive
differences represent greater adjusted decreases in symptoms in the VIPP-SD than in the usual-care group, with the
exception of the SDQ prosocial scale (see footnote d).
b Effect size is the standardised difference in mean (adjusted as above). This is the difference in mean divided by the
SD of controls at follow-up.
c Higher scores on all scales represent higher levels of behaviour problems.
d Higher scores on all scales represent higher levels of behaviour problems, with the exception of the prosocial scale,
where higher scores indicate lower levels of problems.
e Teacher-reported SDQ scores are adjusted for baseline primary caregiver-reported SDQ.
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mean differences and effect sizes, and stronger evidence of group differences in the CACE analysis than
in the ITT analysis. As with the ITT analysis, there is little evidence of a sustained group difference on
the secondary behaviour outcomes (CBCL and SDQ) at the 24-month follow-up in the CACE analysis.
Tables 25–27 in Appendix 4 show the analysis of the secondary behaviour outcomes as reported by
secondary participating caregivers.
Table 10 shows the ITT analysis for secondary outcomes relating to participating caregivers’ reported
parenting practices, mood, anxiety and couple functioning, disaggregated by sex of the reporting caregiver.
There was no evidence of group differences on these secondary outcomes (p-values = 0.15–0.95).
Figures 4 and 5 show exploratory subgroup analyses that disaggregate the adjusted mean difference
between VIPP-SD and usual care on the basis of the child’s age at baseline, the number of participating
caregivers, the severity of baseline SDQ score (by quartile) and the fidelity of the therapist. At the
5-month follow-up, the analysis suggested a greater positive response to treatment in children aged
12–23 months (adjusted mean difference 2.91, 95% CI 0.06 to 5.76), in families with one participating
caregiver (adjusted mean difference 2.79, 95% CI 0.63 to 4.94), those with higher baseline behaviour




(95% CI) Effect sizec (95% CI) p-value
VIPP-SD Usual care
n Mean (SD) n Mean (SD)
PPACSd
Baseline 151 33.5 (9.0) 149 32.4 (10.6)
5 months 140 28.8 (9.2) 146 30.3 (9.9) 2.59 (0.24 to 4.94) 0.26 (0.02 to 0.5) 0.03
24 months 140 23.1 (8.2) 142 24.7 (9.9) 1.96 (–0.30 to 4.23) 0.20 (–0.03 to 0.43) 0.09
CBCLe
Baseline 151 40.7 (21.7) 149 42.7 (21.1)
5 months 140 32.5 (20.6) 145 37.2 (21.0) 3.56 (0.04 to 7.09) 0.17 (0.00 to 0.34) 0.05
24 months 141 30.6 (23.4) 144 35.3 (23.7) 2.90 (–2.19 to 7.98) 0.12 (–0.09 to 0.34) 0.26
SDQe – primary caregiver reported
Baseline 150 13.8 (4.8) 149 14.0 (4.7)
5 months 140 11.3 (5.1) 145 12.2 (5.2) 1.03 (–0.01 to 2.06) 0.20 (0.00 to 0.39) 0.05
24 months 141 10.4 (5.4) 144 10.9 (5.8) 0.32 (–0.91 to 1.56) 0.06 (–0.16 to 0.27) 0.61
SDQe – teacher report
24 months 106 7.1 (6) 104 7.8 (5.7) 0.61 (–1.06 to 2.27) 0.11 (–0.19 to 0.40) 0.48
a The CACE results are based on the assumption that there is no effect of being randomised to VIPP-SD, or of
receiving one, two or three VIPP-SD visits. Receiving four, five or six VIPP-SD visits counts as receiving
the intervention.
b Difference in mean is the difference between treatment groups from linear regression analysis of the outcome
measure on the baseline score of that same measurement, on treatment centre, on randomised group, on length
of follow-up, on age of child and on number of parents/caregivers participating (all treated as fixed effects).
Positive differences represent greater adjusted decreases in symptoms in the VIPP-SD group than in the
usual-care group.
c Effect size is the standardised difference in mean (adjusted as above). This is the difference in mean divided by the
SD of controls at follow-up.
d PPACS results include multiple imputation for those with missing data at follow-up, and for unratable items in the
PPACS scales.
e Higher scores represent higher levels of behaviour problems.
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TABLE 10 Intention-to-treat analysis of secondary outcomes on participating caregivers’ parenting practices, mood,




(95% CI) Effect sizeb (95% CI) p-value
VIPP-SD Usual care
n Mean (SD) n Mean (SD)
Female caregiversc
Parenting Scaled
Baseline 146 2.96 (0.52) 147 2.95 (0.58)
5 months 135 2.90 (0.50) 143 2.90 (0.60) 0.06 (–0.22 to 1.23) 0.11 (–0.37 to 2.06) 0.22
24 months 136 3.02 (0.53) 142 3.02 (0.57) 0.03 (–0.07 to 0.13) 0.06 (–0.12 to 0.23) 0.51
PHQ-9e
Baseline 145 4.34 (4.00) 147 4.28 (4.35)
5 months 135 3.99 (4.49) 144 4.20 (4.71) 0.25 (–0.69 to 1.20) 0.05 (–0.15 to 0.25) 0.60
24 months 136 3.99 (4.60) 141 4.02 (4.22) 0.05 (–0.86 to 0.97) 0.01 (–0.20 to 0.23) 0.91
GAD-7e
Baseline 145 4.89 (4.33) 147 4.73 (4.22)
5 months 134 4.29 (4.46) 144 3.92 (4.00) 0.05 (–0.85 to 0.95) 0.01 (–0.21 to 0.24) 0.91
24 months 136 4.12 (4.64) 141 4.20 (4.09) 0.16 (–0.76 to 1.07) 0.04 (–0.19 to 0.26) 0.74
RDASf
Baseline 130 49.18 (8.36) 126 50.50 (9.22)
5 months 118 49.19 (9.32) 120 49.92 (9.59) 0.20 (–1.44 to 1.83) 0.02 (–0.15 to 0.19) 0.81
24 months 120 50.01 (8.15) 115 50.59 (6.96) –0.40 (–1.78 to 0.99) –0.06 (–0.26 to 0.14) 0.57
Male caregiversg
Parenting Scaled
Baseline 31 2.98 (0.54) 25 2.78 (0.48)
5 months 29 2.90 (0.50) 24 2.89 (0.41) 0.10 (–0.13 to 0.33) 0.24 (–0.32 to 0.8) 0.39
24 months 28 2.9 (0.49) 24 2.95 (0.45) 0.15 (–0.06 to 0.36) 0.34 (–0.13 to 0.82) 0.15
PHQ-9e
Baseline 31 3.03 (2.64) 25 2.56 (2.96)
5 months 29 2.48 (2.34) 24 3.25 (3.57) 0.63 (–0.86 to 2.12) 0.18 (–0.24 to 0.6) 0.40
24 months 28 2.64 (2.15) 24 2.54 (3.08) 0.11 (–1.21 to 1.42) 0.03 (–0.39 to 0.46) 0.87
GAD-7e
Baseline 31 2.35 (2.69) 25 2.84 (2.98)
5 months 29 2.21 (2.32) 24 3.21 (3.66) –0.04 (–1.54 to 1.45) –0.01 (–0.42 to 0.40) 0.95
24 months 28 2.54 (2.32) 24 2.50 (2.70) –0.51 (–1.59 to 0.57) –0.19 (–0.59 to 0.21) 0.35
continued
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FIGURE 4 Forest plot for exploratory subgroup analyses at the 5-month follow-up.
TABLE 10 Intention-to-treat analysis of secondary outcomes on participating caregivers’ parenting practices, mood,




(95% CI) Effect sizeb (95% CI) p-value
VIPP-SD Usual care
n Mean (SD) n Mean (SD)
RDASf
Baseline 31 50.56 (5.20) 25 50.23 (6.51)
5 months 29 50.38 (6.42) 24 48.31 (8.80) 0.11 (–3.42 to 3.65) 0.01 (–0.39 to 0.41) 0.95
24 months 27 51.37 (4.87) 24 48.82 (6.78) –1.27 (–3.97 to 1.42) –0.19 (–0.59 to 0.21) 0.35
a Difference in mean is the difference between treatment groups from linear regression analysis of the outcome
measure on the baseline score of that same measurement, on treatment centre, on randomised group, on length of
follow-up, on age of child and on number of caregivers participating (all treated as fixed effects). Positive differences
represent greater adjusted decreases in symptoms in the VIPP-SD than in the usual-care group in all cases but the
RDAS (see footnote g).
b Effect size is the standardised difference in mean (adjusted as above). This is the difference in mean divided by the
SD of controls at follow-up.
c Female caregivers consisted of 287 primary caregivers at baseline, 271 at the 5-month follow-up, and 272 at the
24-month follow-up, as well as eight participating female secondary caregivers at each time point. Two families had
both a female primary and female secondary caregiver participating. In these cases, the scores from these caregivers
were averaged prior to inclusion in the above analysis.
d Higher scores indicate more ineffective parenting strategies.
e Higher scores represent higher symptom severity.
f Higher scores indicate greater relationship satisfaction and lower scores indicate greater relationship distress.
g Male caregivers consisted of 13 primary caregivers at baseline and the 5- and 24-month follow-ups; and
43 participating male secondary caregivers at baseline, 40 at 5-month follow-up, and 39 at 24-month follow-up.
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scores (as indicated by total scores in the third quartile: adjusted mean difference 6.42, 95% CI 1.61 to
11.23; and fourth quartile: adjusted mean difference 3.48, 95% CI 0.03 to 6.93; of the baseline SDQ),
and those who had received the programme from a therapist rated high (adjusted mean difference
3.47, 95% CI 0.83 to 6.12), but not the highest, on fidelity. At the 24-month follow-up, larger effects
remained in the families with one participating caregiver (adjusted mean difference 2.19, 95% CI
0.00 to 4.39) and those who had received the programme from a therapist rated with high (adjusted
mean difference 3.51, 95% CI 0.88 to 6.14), but not the highest, fidelity scores. Appendix 6 shows the
subgroup analysis for baseline behaviour based on quartiles of externalising scores on the SDQ at the
5- and 24-month follow-ups (see Appendix 6, Figures 13 and 14).
The age of a child at baseline and the number of participating caregivers were predefined subgroup
analyses. Analyses by quartile of SDQ (at baseline) and (in those randomised to VIPP-SD) by fidelity of
the intervention (compared with those randomised to usual care) are post hoc. Fidelity is independently
assessed, based on the fidelity of the therapist; ‘fidelity zero’ represents a family who completed fewer
than four VIPP-SD visits, despite being randomised to VIPP-SD.
Missing data
Eleven participants (7%) allocated to the VIPP-SD group and three participants (2%) allocated to
the usual-care group were not assessed for the primary outcome measure (PPACS) at the 5-month
follow-up. Eleven participants (7%) allocated to the VIPP-SD group and seven participants (5%)
allocated to the usual-care group were not assessed for the primary outcome measure (PPACS) at
the 24-month follow-up. Baseline characteristics of participants with and without missing primary
outcome data are given in Appendix 5, Table 29.
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FIGURE 5 Forest plot for exploratory subgroup analyses at the 24-month follow-up.
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Blinding
Outcome assessors reported having been unblinded for 11 participants (4%) [seven (5%) in the VIPP-SD
group and four (3%) in the usual-care group] as a result of participants informing assessors of their
treatment allocation at their 5-month follow-up visit. At the 24-month follow-up visit, five participants
(2%) [three in the VIPP-SD group and two in the usual-care group] informed assessors of their allocation.
In instances where unblinding occurred before the primary outcome had been collected, the audio-
recording of the interview was double-scored by a second assessor, who remained blinded to allocation,
to minimise the risk of bias. Assessors who were unblinded at the 5-month follow-up assessment did not
collect primary outcome data from the same family at the 24-month follow-up visit.
Acceptability
Participants allocated to the VIPP-SD group were invited to complete a feedback questionnaire at the
end of treatment. Of the 139 participants who received at least one therapy session, 39 (28%) returned
the feedback questionnaire. Seven families included two participating caregivers who each completed
a questionnaire, giving a total of 46 respondents. Table 11 shows that approximately two-thirds to
three-quarters of respondents endorsed the programme’s positive impact on their relationship with
their child; their understanding of their child’s thoughts, feelings, behaviours, and likes and dislikes;
as well as their reactions to their child’s behaviour and communication. All respondents reported that
their preferred setting for the programme was in the home. The main reasons endorsed by participants
were that the home setting removed the need for travel and reflected everyday interactions (Table 12).
TABLE 11 Participants’ responses to the intervention feedback questionnaire: perceived positive impact of VIPP-SD
How much do you think the visits have
impacted on your . . .




A lot/a great deal,
n (%)
Relationship with your child 13 (28) 17 (37) 16 (35)
Understanding of your child’s thoughts and feelings 9 (20) 16 (35) 21 (46)
Understanding of your child’s behaviour 9 (20) 17 (37) 20 (43)
Reaction to your child’s behaviour 12 (26) 12 (26) 22 (48)
Understanding of your child’s likes and dislikes 17 (37) 17 (37) 12 (26)
Communication with your child 12 (26) 17 (37) 17 (37)
Note
Caregivers (N= 46) were from 39 participating families; of these, 32 were from families with one participating
caregiver and 14 were from families with two participating caregivers.
TABLE 12 Participants’ responses to the intervention feedback questionnaire: perceptions of
treatment setting
I found that having the sessions delivered in my home was
helpful because . . . n (%)
I did not have to pay for transport 18 (39)
I did not have to arrange childcare 25 (54)
I did not spend time travelling 39 (85)
It reflected everyday interaction 37 (80)
I have not found the home-based delivery format helpful 0 (0)
Note
Caregivers (N= 46) were from 39 participating families; of these, 32 were from families with
one participating caregiver and 14 were from families with two participating caregivers.
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Serious adverse events
During the study, there were three children (2%) admitted to hospital in the VIPP-SD group by the
5-month follow-up and 10 children (7%) were admitted by the 24-month follow-up. In the usual-care
group, there were four children (2%) admitted to hospital by the 5-month follow-up and eight children
(5%) by the 24-month follow-up. All admissions reasons were unrelated to treatment and study
procedures (e.g. accidents and respiratory infections). There was no evidence of group differences and
no other adverse events were reported. Protocol deviations and violations are detailed in Appendix 7.
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Chapter 4 Economic evaluation
Aim
The aim of the economic evaluation was to assess the cost-effectiveness of VIPP-SD compared with
usual care at 24 months post randomisation.
Methods
Perspective
The economic evaluation took the NHS/Personal Social Services (PSS) perspective preferred by NICE,65
and included the use of all health and social services by the child and by parent/caregivers in relation
to their child’s needs over the 24-month follow-up.
Method of economic evaluation
Short-term cost-effectiveness
The primary economic evaluation explored cost-effectiveness at the 24-month follow-up in terms of
the primary clinical outcome measure (PPACS). In addition, a cost–consequences analysis outlining
costs alongside the key secondary outcome measures (CBCL and SDQ) explored the potential
economic impacts of the intervention more broadly.
Long-term cost-effectiveness
A longer-term analysis aimed to explore the cost–utility of VIPP-SD beyond the trial follow-up period
by utilising data from the trial and supplementing it with available data from the literature using
decision-analytic modelling techniques.
Costs
Information on the use of health and social care services was recorded in interviews using a modified
version of the CA-SUS. Modifications to the CA-SUS were based on a review of recent literature
and clinical feedback. Data were collected on the use of accommodation services (e.g. foster care
and supported housing), hospital services (e.g. inpatient stays, outpatient contacts, accident and
emergency attendances), community-based health and social care services (e.g. contacts with GPs
and clinical psychologists), and all prescribed medication. Parents/caregivers were interviewed at
baseline and asked about their child’s use of services and/or their own use of services relating to their
child’s needs in the previous 3 months. At subsequent follow-up points (5 and 24 months), service
use was recorded for the period since the previous interview to ensure that the entire duration of
the trial had been captured.
For each item of service use reported in the CA-SUS, a nationally applicable unit cost was applied
to calculate the total costs for each participant. Unit costs for hospital services were sourced from
the NHS Reference Costs 2017–18.66 Costs from the annually published unit costs of health and social
care compendium67 were applied to community-based health and social care, and Local Authority
accommodation services. Costs applied to accommodation services were also sourced from UK
government web pages.68,69 The costs of medications were based on prices listed in the British National
Formulary70 for the generic drug, and were calculated based on dosages reported in the CA-SUS, or
national averages for young children if left unspecified.70 Unit costs applied were for the financial year
2017–18 (Table 13) and are reported in Great British pounds. Costs incurred after 12 months from the
start of the trial were discounted by 3.5%, as recommended by NICE.65
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The cost of delivering VIPP-SD was calculated using a standard micro-costing (bottom-up) approach
(outlined for a band 6 NHS therapist in Table 14) and included therapist salaries plus on-costs (employers’
national insurance and superannuation contributions) and appropriate capital, administrative and managerial
overheads, as well as the costs of training, supervision and equipment.65,71 Data on intervention contacts and
the costs of training and materials were collected directly from trial records, and indirect time (preparation,
supervision, administration, travel, etc.) was estimated using questionnaires completed by each therapist
delivering the intervention on the time they spent on different activities. Intervention costs were calculated




The use of health and social care services is reported by trial group as the mean, SD and range, as
well as by the percentage of the sample for each group that had at least one contact. Differences in
resource use were not tested for statistical significance to avoid excessive significance testing and to
keep the focus of the economic analysis on cost and cost-effectiveness.
For each participant, all costs were summed to calculate total costs over the 24-month follow-up period.
Costs and outcomes, including costs per sector, were summarised using the mean and standard error for
each trial group, and the differences between the two were compared using standard parametric t-tests.
Despite the skewed nature of cost data, this method allows inferences to be made about the arithmetic
mean, which is more meaningful from a decision-making perspective.72
Cost-effectiveness of VIPP-SD was explored in terms of the primary outcome measure (PPACS) and
assessed (1) through the calculation of incremental cost-effectiveness ratios (ICERs) (i.e. the additional
TABLE 13 Unit costs and sources used for the economic evaluation
Service
Unit cost or
range (£) Source Notes
Hospital inpatient (per night) 484.89–643.80 NHS Reference Costs
2017–1866
Weighted average of short and long stay
Hospital outpatient
(per appointment)
48.81–751.12 NHS Reference Costs
2017–1866
Varied by specialty reported in the CA-SUS;
unit cost for paediatrics (£198.20) applied if




148.36–247.50 NHS Reference Costs
2017–1866
Varied by if ambulance services were used
Community-based health
care, e.g. GP, district nurse
(per minute of contact)
0.60–3.10 Curtis 201767 Varied by specialist seen and duration of
contact reported in the CA-SUS
Community-based social
care, e.g. social services
youth worker (per minute
of contact)
0.52–0.98 Curtis 201767 Varied by specialist seen and duration of
contact reported in the CA-SUS




Medication (per day) 0.02–1.37 British National Formulary70 Varied by medication type and dosage
reported in the CA-SUS
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cost of one intervention compared with another, divided by the additional effect73) and (2) using the net
monetary benefit (NMB) approach based on the use of a linear function of cost and effects and assuming
specified values for the willingness-to-pay (WTP) for each additional unit of effect.74 Uncertainty around
the mean estimates of cost and outcome was explored by generating 1000 bootstrap iterations and
plotting these on a cost-effectiveness plane for interpretation.75 A cost-effectiveness acceptability curve
(CEAC)76 was then constructed to examine the probability of VIPP-SD being cost-effective compared
with usual care for a range of possible values of WTP per unit improvement in outcome. This analysis
was based on 30 multiply imputed data sets of total costs and outcomes using chained equations and
predictive mean matching.
A prespecified sensitivity analysis was carried out to explore cost-effectiveness in terms of PPACS
score at the 24-month follow-up for complete cases and excluding influential outliers (participants
with total costs in the 99th percentile77) to examine the sensitivity of the cost-effectiveness results
to missing data and MI. A second sensitivity analysis explored cost-effectiveness using the PPACS
score at the 5-month follow-up, in line with the primary clinical end point.
All economic analyses were adjusted for recruitment centre, age of child at recruitment, parental
involvement (one or two participating parents/caregivers) and time to follow-up, in line with clinical
analyses, plus the baseline variable of interest (cost, PPACS, CBCL, SDQ). Analyses were conducted in
Stata/SE® version 15.
Long-term analyses
The economic implications of behavioural problems are long term in nature, with childhood behaviour
problems being linked to later delinquency and criminality, and affecting future mental health status and
education and employment outcomes.78,79 Should the trial results suggest that VIPP-SD has an impact on
outcomes at the 24-month follow-up, which is suggestive of possible future cost-effectiveness differences
TABLE 14 Costing schema for calculation of intervention costs
Cost and unit
estimation 2017–18 value Notes
Wages/salarya £31,593 Based on a health visitor (pay band 6) delivering the intervention
Salary oncostsa £7791 Includes employer’s contributions to national insurance and superannuation
Overheadsa £24,694 Includes costs for management, administration and estates staff,
plus non-staff costs
Capital overheadsa £5125
Working timea 1599 hours per year Based on 42.6 weeks per year, 37.5 hours per week
Face-to-face timeb 1 : 2.25 Based on each hour of intervention delivery requiring 2.25 hours of
preparation and administration time
VIPP-SD deliveryb £140.65 per hour
Supervisionb £21.80 per hour of
delivery
Based on each hour of intervention delivery requiring 0.25 hours of
supervision by a senior clinician (pay band 8c)
Training and
equipmentc
£12.16 per hour of
delivery
Includes costs of training sessions, manuals and therapist kits [with toys,
camera, digital voice recorder; costs were annuitised over 3 years. Costs for
data storage and file-sharing platform were not included
Length of sessionsc 1.5 hours Cost per session per participant: £261.92
a Sourced from the annual unit costs of health and social care publication.67
b Estimated from questionnaires completed by therapists delivering the intervention and clinicians supervising delivery
for the trial.
c Estimated from trial administration data.
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between the two groups, longer-term cost-effectiveness will be explored using decision-analytic modelling,
following methods applied in similar research.16 As no method of direct estimation of health-related quality
of life, and thus quality-adjusted life-years (QALYs), preferred for health economic evaluation,65 currently
exists for infants and preschool children, effectiveness differences at the 24-month follow-up were
checked for longer-term implications using the SDQ, for which a mapping function to generate QALYs
from the Child Health Utility index 9D (CHU-9D)80 exists.81 The five SDQ subscale scores (i.e. emotion,
conduct, hyperactivity, peer and prosocial) were transformed using the published algorithm to give utility
weights that were used to calculate QALYs using the area under the curve approach.82
Results
Data completeness
The availability of resource use data at each assessment time point is summarised in Table 15. Data for
all periods (baseline and 5- and 24-month follow-ups) were available for 140 participants (93%) in the
VIPP-SD group and 142 participants (95%) in the usual-care group.
Resource use over the 24-month follow-up
Intervention
A summary of the VIPP-SD intervention sessions completed by the trial participants is presented in
Table 16. The majority of participants in the VIPP-SD trial group (82.86%) completed all six intervention
sessions, whereas very few (5.71%) completed no sessions.
Hospital, community-based and accommodation services
Table 17 summarises the use of health and social care services over the 24-month follow-up period.
Overall, all services were accessed by similar proportions of participants across the trial groups.
For hospital services, mean inpatient stay was higher in the VIPP-SD group (0.78 nights, SD 6.03) than
in the usual-care group (0.18 nights, SD 0.71) and was used by a slightly higher proportion of participants
(14% vs. 11%). For community-based services, some were used more by VIPP-SD participants than
usual care participants, including GP telephone calls (46% vs. 30%) and practice nurses (76% vs. 69%),
and some were used less by VIPP-SD participants, including district nurses (39% vs. 55%) and speech
and language therapists (12% vs. 23%). However, few differences were evident overall. Very few
accommodation services were used and these were used by a very small proportion of the sample (1%)
across the trial groups.
Medication
The use of prescribed medication is summarised in Table 18. Antibiotics, corticosteroids and
bronchodilators were the most commonly used medications across trial groups, whereas some
medication types (i.e. antiepileptic, antihypertensive and antiseptic) were used in the VIPP-SD group
only and were used by a very small proportion of the sample (1% for each).
TABLE 15 Availability of resource use data
Assessment period
Trial group, n (%)
VIPP-SD Usual care
Baseline 151 (100) 149 (100)
5 months 147 (97) 147 (99)
24 months 140 (93) 142 (95)
All periods 140 (93) 142 (95)
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TABLE 16 Uptake of VIPP-SD intervention sessions by participants randomised to the intervention
Number of sessions
Attendance of participants









a This n relates to the estimation sample used for the primary economic analysis (i.e. those
participants with 24-month follow-up data).
b Completing four or more sessions of VIPP-SD was considered as being compliant with
the intervention.
TABLE 17 Use of health and social care services over 24 months’ follow-up
Service
Trial group
VIPP-SD (n= 140) Usual care (n= 142)
Mean (SD) Range
Percentage




Inpatient (nights) 0.78 (6.03) 0–70 14 0.18 (0.71) 0–5 11
Outpatient (appointments) 1.11 (2.61) 0–16 36 1.22 (2.43) 0–17 38
A&E (attendances) 1.19 (2.71) 0–28 51 0.92 (1.28) 0–6 49
Ambulance (attendances) 0.20 (0.95) 0–10 11 0.13 (0.43) 0–3 11
Community health and social care (contacts)
GP home 0.01 (0.08) 0–1 1 0.01 (0.08) 0–1 1
GP surgery 3.99 (4.91) 0–50 86 4.06 (4.10) 0–25 85
GP telephone 1.21 (2.11) 0–10 46 0.98 (2.28) 0–15 30
Practice nurse 1.16 (1.01) 0–5 76 1.06 (0.97) 0–4 69
District nurse 0.99 (2.14) 0–18 39 1.14 (2.62) 0–25 55
Community paediatrician 0.06 (0.30) 0–2 5 0.09 (0.37) 0–2 6
Clinical psychologist 0.09 (0.47) 0–3 4 0.30 (2.64) 0–31 4
Speech and language therapist 0.70 (2.67) 0–23 12 1.44 (7.57) 0–87 23
Child psychiatrist 0.01 (0.08) 0–1 1 0.01 (0.08) 0–1 1
Parent training 1.04 (3.57) 0–21 12 1.34 (4.26) 0–30 15
Parenting group 0.04 (0.36) 0–3 1 0.06 (0.67) 0–8 1
Family therapist 0.14 (1.39) 0–16 1 0.16 (1.31) 0–12 2
CAMHS 0.24 (1.81) 0–20 4 0.42 (2.41) 0–20 4
continued
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TABLE 17 Use of health and social care services over 24 months’ follow-up (continued )
Service
Trial group
VIPP-SD (n= 140) Usual care (n= 142)
Mean (SD) Range
Percentage
using Mean (SD) Range
Percentage
using
Occupational therapist 0.19 (1.70) 0–20 4 0.76 (6.93) 0–81 4
Physiotherapist 0.07 (0.49) 0–4 3 0.08 (0.40) 0–3 4
Nutritionist 0.09 (0.51) 0–5 5 0.15 (0.70) 0–6 7
Genetic testing 0.01 (0.12) 0–1 1 0.01 (0.08) 0–1 1
Art/music therapist 0.29 (2.07) 0–20 2 – – –
Dentist 1.98 (1.47) 0–8 82 2.23 (1.65) 0–8 85
Social worker 0.14 (0.78) 0–6 4 0.33 (1.94) 0–20 6
Family support worker 0.44 (1.99) 0–16 6 0.60 (2.98) 0–25 7
Portage worker – – – 0.06 (0.67) 0–8 1
Accommodation key worker – – – 0.25 (2.69) 0–32 3
Social services youth worker – – – – – –
Accommodation (nights)
Bed and breakfast 0.45 (5.32) 0–63 1 – – –
Supported housing – – – 0.98 (11.66) 0–139 1
Foster care – – – – – –
Kinship care – – – – – –
Residential care – – – – – –
Mother and baby care – – – – – –
Refuge – – – – – –
A&E, accident and emergency; CAMHS, Child and Adolescent Mental Health Services.
TABLE 18 Use of medication over 24 months’ follow-up
Medication type
Trial group, percentage using
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Costs
The total costs at the 5- and 24-month follow-up points, as well as the costs per sector and the costs
at baseline, are summarised in Table 19. At the 24-month follow-up (primary economic end point), the
mean total costs were significantly higher in the VIPP-SD group (£3131.93; SD £416.54) than in the
usual-care group (£1525.38; SD £293.49). The difference in total costs between the trial groups was
£1449.99 (adjusted mean difference, 95% CI £619.45 to £2280.52), which was driven mainly by the
cost of the intervention (mean £1466.28, standard error £46.47). Results were similar at the 5-month
follow-up (primary clinical end point), being significantly higher in the VIPP-SD group than in the
usual-care group (adjusted mean difference £1281.34, 95% CI £1022.40 to £1540.29).
Outcomes
Table 20 summarises the PPACS score outcomes at baseline, and at the 5- and 24-month follow-ups
used in the cost-effectiveness analysis. The PPACS scores were poorer in the VIPP-SD group than
in the usual-care group at baseline (mean 33.61 for VIPP-SD vs. mean 32.27 for usual care), but
improved and were better in the VIPP-SD group at 5 months (mean 28.79 for VIPP-SD vs. mean
30.28 for usual care) and 24 months (mean 23.12 for VIPP-SD vs. mean 24.68 for usual care). As outlined
in the clinical results, these differences were statistically significant at 5 months (adjusted mean
difference –2.55, 95% CI –4.70 to –0.39) and similar but not significant at 24 months (adjusted mean
TABLE 19 Mean costs (£) per participant over 24 months’ follow-up
Cost category





differenceb 95% CI p-value
Baseline n = 147 n = 147
Total 297.77 (102.56) 385.97 (72.52) –88.87 –61.47 –276.26 to 153.33 0.574
5-month follow-up n = 147 n = 147
Intervention 1458.51 (46.59) 0.00 (0.00) 1423.85 1423.65 1320.09 to 1527.22 < 0.001
Hospital services 143.14 (40.35) 151.16 (28.53) –7.14 –13.84 –101.37 to 73.69 0.759
Community-based
services
221.34 (87.95) 315.63 (62.19) –95.20 –133.65 –319.59 to 52.29 0.158
Accommodation
services
0.00 (0.00) 36.92 (26.10) –37.72 –16.86 –94.22 to 60.49 0.668
Medication 4.56 (1.63) 6.47 (1.15) –1.90 –2.64 –6.20 to 0.93 0.147
Total 1827.55 (120.71) 510.18 (85.35) 1281.89 1281.34 1022.40 to 1540.29 < 0.001
24-month follow-up n = 140 n = 142
Intervention 1466.28 (46.47) 0.00 (0.00) 1423.85 1430.17 1335.55 to 1524.79 < 0.001
Hospital services 841.27 (360.78) 439.91 (254.20) 397.58 312.87 –396.63 to 1022.36 0.386
Community-based
services
755.35 (194.11) 1020.52 (136.77) –284.77 –317.21 –685.63 to 51.22 0.091
Accommodation
services
32.17 (50.02) 38.22 (35.24) –10.37 1.90 –110.25 to 114.06 0.973
Medication 36.85 (8.41) 26.74 (5.93) 9.75 10.73 –6.48 to 27.94 0.221
Total 3131.93 (416.54) 1525.38 (293.49) 1536.05 1449.99 619.45 to 2280.52 0.001
SE, standard error.
a Comparison based on multiply imputed data.
b Adjusted for recruitment centre, age of child at recruitment, number of caregivers participating, time to follow-up
and baseline score.
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difference –1.87, 95% CI –4.10 to 0.37). Results from the clinical analysis of PPACS scores (see Table 6)
are very similar to the economic analysis, which used a separate imputation protocol combining both
outcomes and costs.
Cost-effectiveness analysis using Preschool Parental Account of Children’s
Symptoms at 24-month follow-up
The results of the primary cost-effectiveness analysis using PPACS as the outcome of interest suggest
that VIPP-SD is more costly and more effective than usual care. Figure 6 shows the scatterplot of
bootstrapped mean differences in costs and PPACS score. The majority of scatter points (98%) lie in
the north-east quadrant, where VIPP-SD is more costly and more effective, whereas the remaining
scatter points (2%) lie in the north-west quadrant, where VIPP-SD is more costly and less effective.
TABLE 20 Mean PPACS scores per participant applied to the cost-effectiveness analysis
PPACSa time point
Trial group
VIPP-SD minus usual carebVIPP-SD Usual care




differencec 95% CI p-value
Baseline 151 33.61 (1.15) 149 32.27 (0.81) 1.25 0.98 –1.58 to 3.55 0.450
5 months 140 28.79 (1.14) 146 30.28 (0.80) –1.62 –2.55 –4.70 to –0.39 0.021
24 months 140 23.12 (1.08) 142 24.68 (0.76) –1.48 –1.87 –4.10 to 0.37 0.102
SE, standard error.
a Lower scores indicate better outcomes.
b Comparison based on multiply imputed data.
c Adjusted for recruitment centre, age of child at recruitment, number of caregivers participating, time to follow-up
and baseline score.
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FIGURE 6 Bootstrapped mean differences in costs and PPACS scores at the 24-month follow-up. NE, north-east
(more costly, more effective); NW, north-west (more costly, less effective); SE, south-east (less costly, more effective);
SW, south-west (less costly, less effective).
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The CEAC for the primary cost-effectiveness analysis (Figure 7) indicates that VIPP-SD has a higher
probability of being cost-effective than usual care at WTP thresholds > £800 for a 1-point improvement
in PPACS score on a scale of 0–70 points (equivalent to 0.10 SD based on usual-care group SD post
treatment). However, it is not possible to make firm conclusions about the cost-effectiveness of VIPP-SD
without agreed thresholds for society’s WTP for improvements in PPACS score.
Sensitivity analyses
The results of the two sensitivity analyses – (1) examining the effect of multiple imputation and
(2) examining the results at the 5-month follow-up – are presented in Table 21. The distribution of
WTP threshold for 1-point improvement in PPACS score (£)



































FIGURE 7 Cost-effectiveness acceptability curve showing the probability that VIPP-SD is cost-effective compared with
usual care at different values of WTP thresholds for a 1-point improvement in PPACS score at the 24-month follow-up.
The dashed line represents the point at which a probability of 0.5 (50%) is reached.
TABLE 21 Mean total cost (£) and outcomes per participant for sensitivity analyses
Analysis





differencea 95% CI NW NE SW SE
Base case n = 140 n = 142
Total cost (£) 3131.93 (416.54) 1525.38 (293.49) 1449.99b 619.45 to 2280.52b 2 98 0 0
PPACS scorec 23.12 (1.08) 24.68 (0.76) –1.87b –4.10 to 0.37b
Complete cases n = 137d n = 142
Total cost (£) 2638.89 (231.84) 1525.38 (162.46) 1175.17 730.42 to 1619.92 7 93 0 0
PPACS scorec 23.14 (1.10) 24.68 (0.78) –1.85 –3.85 to 0.15
5-month follow-up n = 128 n = 124
Total cost (£) 1827.55 (120.71) 510.18 (85.35) 1281.34b 1022.40 to 1540.29b 0 100 0 0
PPACS scorec 28.68 (1.22) 30.34 (0.87) –2.55b –4.70 to –0.39b
NE, north-east (more costly, more effective); NW, north-west (more costly, less effective); SE, south-east (less costly,
more effective); SW, south-west (less costly, less effective).
a Adjusted for recruitment centre, age of child at recruitment, number of caregivers participating, time to follow-up
and baseline score.
b Comparison based on multiply imputed data.
c Lower scores indicate better outcomes.
d Excluding influential outliers, i.e. participants with total costs in the 99th percentile.
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bootstrap iterations across the cost-effectiveness plane changes for both analyses compared with base
case, but, in both cases, the majority of scatter points fall in the north-east quadrant, indicating that
the VIPP-SD group has better outcomes but also higher costs than the usual-care group.
In the sensitivity analysis considering complete cases and excluding influential outliers, the adjusted
difference in mean costs is lower (£1175.17) than in the base-case analysis (£1449.99); meanwhile, the
PPACS scores remain relatively unchanged. In the sensitivity analysis examining results at the 5-month
follow-up, the adjusted mean difference is greater for both the costs (£1281.34) and PPACS score
(–2.55) than in the base-case analysis (£1449.99 and –1.87, respectively).
The cost-effectiveness results of the sensitivity analysis considering complete cases and excluding
influential outliers were very similar to those of the base-case analysis. The scatterplot of bootstrapped
mean differences and PPACS scores for this analysis (Figure 8) shows that the majority of scatter
points (93%) lie in the north-east quadrant (i.e. VIPP-SD is more costly and more effective than usual
care) whereas the remaining scatter points (7%) lie in the north-west quadrant, suggesting that VIPP-SD
is more costly and less effective than usual care. The CEAC for this analysis (Figure 9) suggests that
VIPP-SD has a higher probability of being cost-effective than usual care for WTP thresholds > £800
for a 1-point improvement in PPACS score on a scale of 0–70 points (equivalent to 0.10 SD based on
usual-care group SD post treatment).
The cost-effectiveness results at the 5-month follow-up were also similar to those in the base-case
analysis. The scatterplot of bootstrapped mean differences and PPACS scores for this analysis (Figure 10)
shows that almost 100% of the scatter points lie in the north-east quadrant, suggesting that VIPP-SD
is more costly and more effective than usual care. The CEAC for this analysis (Figure 11) suggests that
VIPP-SD has a higher probability of being cost-effective than usual care for WTP thresholds > £625
for a 1-point improvement in PPACS score on a scale of 0–70 points (equivalent to 0.10 SD based on
usual-care group SD at post treatment).
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FIGURE 8 Bootstrapped mean differences in costs and PPACS scores at the 24-month follow-up: complete cases and
excluding influential outliers. NE, north-east (more costly, more effective); NW, north-west (more costly, less effective);
SE, south-east (less costly, more effective); SW, south-west (less costly, less effective).
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Cost–consequences analysis at the 24-month follow-up
The 24-month costs and the key secondary outcome measures are summarised in Table 22. Alongside
significantly higher costs, there were no significant differences in either the CBCL or the SDQ at the
24-month follow-up, although observed differences were generally in favour of the VIPP-SD group.
A similar pattern was seen for the additional secondary outcome measures (Parenting Scale, PHQ-9,
GAD-7, RDAS; see Table 10). These results suggest that the application of an alternative secondary
outcome measure would produce similar results to those already demonstrated using the PPACS.
WTP threshold for 1-point improvement in PPACS score (£)



































FIGURE 9 Cost-effectiveness acceptability curve showing the probability that VIPP-SD is cost-effective compared with
usual care at different values of WTP thresholds for a 1-point improvement in PPACS score at the 24-month follow-up:
complete cases and excluding influential outliers. The dashed line represents the point at which a probability of 0.5 (50%)
is reached.
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FIGURE 10 Bootstrapped mean differences in costs and PPACS scores at the 5-month follow-up. NE, north-east
(more costly, more effective); NW, north-west (more costly, less effective); SE, south-east (less costly, more effective);
SW, south-west (less costly, less effective).
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FIGURE 11 Cost-effectiveness acceptability curve showing the probability that VIPP-SD is cost-effective compared with
usual care at different values of WTP thresholds for a 1-point improvement in PPACS score at the 5-month follow-up.
The dashed line represents the point at which a probability of 0.5 (50%) is reached.
TABLE 22 Cost–consequences analysis at the 24-month follow-up
Outcome measure
Trial group
VIPP-SD minus usual careaVIPP-SD Usual care
n Mean (SE) n Mean (SE)
Adjusted
differenceb 95% CI p-value
Total costs 140 3131.93 (416.54) 142 1525.38 (293.49) 1449.99 619.45 to 2280.52 < 0.01
PPACSc 140 23.12 (1.08) 142 24.68 (0.76) –1.87 –4.10 to 0.37 0.10
CBCLc 140 30.58 (2.79) 144 35.31 (1.96) –2.81 –7.22 to 2.07 0.24
SDQc 141 10.40 (0.66) 144 10.92 (0.47) –0.26 –1.39 to 0.88 0.66
Female caregivers
Parenting Scaled 136 3.02 (SD 0.53) 142 3.02 (SD 0.57) 0.03 –0.07 to 0.13 0.51
PHQ-9d 136 3.99 (SD 4.60) 141 4.02 (SD 4.22) 0.05 –0.86 to 0.97 0.91
GAD-7d 136 4.12 (SD 4.64) 141 4.20 (SD 4.09) 0.16 –0.76 to 1.07 0.74
RDASd 120 50.01 (SD 8.15) 115 50.59 (SD 6.96) –0.40 –1.78 to 0.99 0.57
Male caregivers
Parenting Scaled 28 2.9 (SD 0.49) 24 2.95 (SD 0.45) 0.15 –0.06 to 0.36 0.15
PHQ-9d 28 2.64 (SD 2.15) 24 2.54 (SD 3.08) 0.11 –1.21 to 1.42 0.87
GAD-7d 28 2.54 (SD 2.32) 24 2.50 (SD 2.70) –0.51 –1.59 to 0.57 0.35
RDASd 27 51.37 (SD 4.87) 24 48.82 (SD 6.78) –1.27 –3.97 to 1.42 0.35
SE, standard error.
a Comparison based on multiply imputed data.
b Adjusted for recruitment centre, age of child at recruitment, number of caregivers participating, time to follow-up
and baseline score.
c Lower scores indicate better outcomes.
d Values reproduced from Table 10.
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Long-term cost-effectiveness
Table 23 reports the utilities and QALYs generated using the mapping algorithm for the SDQ. As a
result of the small difference between trial groups in SDQ scores (see Table 22), the utilities generated
from the SDQ were similar between the two groups, which resulted in very small differences in QALYs
at the 5-month follow-up (unadjusted and adjusted difference 0.010) and at the 24-month follow-up
(unadjusted difference 0.007, adjusted difference 0.003). These small differences in mapped QALYs
between trial groups at the 24-month follow-up, alongside no difference in costs, with the exception
of the cost of the VIPP-SD intervention, are not suggestive of possible future cost-effectiveness




The primary cost-effectiveness analysis suggests that VIPP-SD is associated with higher health and
social care costs as a result of the additional cost of the VIPP-SD intervention and non-significant
observed differences in PPACS scores that favour the intervention over usual care. When combined,
the probability of VIPP-SD being cost-effective compared with usual care increases as the WTP
for improvements in PPACS score increases, with VIPP-SD having the higher probability of being
cost-effective at WTP values of approximately £800 and above per 1-point improvement in PPACS
score (equivalent to 0.10 SD based on usual-care group SD at post treatment). Because the PPACS
is not associated with a WTP threshold to support decision-making (compared with QALYs with a
NICE WTP threshold of £20,000–30,000 per QALY), it is not possible to come to any firm conclusion
about the relative cost-effectiveness of VIPP-SD in the short term. These results were robust to
changes in assumptions in sensitivity analyses (complete case, excluding outliers and analysis at
the 5-month follow-up).
TABLE 23 Mean utility scores and QALYs per participant mapped from the SDQ
Quality of lifeb,c
Trial group
VIPP-SD minus usual careaVIPP-SD Usual care




differenced 95% CI p-value
Baseline (utility) 150 0.820 (0.006) 149 0.817 (0.004) 0.003 0.003 –0.008 to 0.014 0.576
5 months (utility) 140 0.836 (0.006) 145 0.830 (0.004) 0.004 0.006 –0.003 to 0.015 0.209
24 months (utility) 141 0.842 (0.007) 144 0.838 (0.005) 0.003 0.001 –0.011 to 0.012 0.926
5 months (QALYs) 139 0.345 (0.002) 145 0.343 (0.002) 0.001 0.001 –0.001 to 0.003 0.206
24 months (QALYs) 140 1.632 (0.011) 144 1.620 (0.007) 0.007 0.003 –0.011 to 0.173 0.656
SE, standard error.
a Comparison based on multiply imputed data.
b Higher scores indicate better outcomes.
c Mapped from SDQ subscale scores.
d Adjusted for recruitment centre, age of child at recruitment, number of caregivers participating, time to follow-up
and baseline score.
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The cost of the VIPP-SD intervention was the key cost driver in the cost-effectiveness analyses
presented. As such, it is important to note that intervention costs commonly reduce in the longer
term, as therapists become more experienced, and service providers and commissioners benefit from
both experience and economies of scale. In particular, the average length of sessions provided in
the current trial was 1.5 hours, which may be longer than when sessions are completed by more
experienced therapists, as all of the VIPP-SD trial therapists were new to the VIPP-SD intervention
and had been trained only recently. This should be considered in relation to any longer-term plans to
invest in VIPP-SD for this population.
The lack of differences in the SDQ at the 24-month follow-up precluded longer-term decision
modelling as there was no evidence, using the prespecified measure of outcome, of a difference
relating to effectiveness or, indeed, costs (excluding the cost of VIPP-SD). This conclusion may have
differed if the focus had been on the PPACS, but, unlike the SDQ, the PPACS is not associated with
either a mapping algorithm capable of generating QALYs or any suitable longitudinal data to identify
future service use, costs or effects; thus, the use of the PPACS for modelling was not feasible.
Strengths and limitations
The economic evaluation benefited from a large sample with data collected through a robust and
scientifically rigorous RCT. Although it is difficult to come to any firm conclusions regarding the
cost-effectiveness of VIPP-SD compared with usual care, as this is the first cost-effectiveness analysis
of VIPP-SD, the study provides valuable information that supports the methodological development of
future economic evaluations.
The lack of a WTP threshold for the PPACS was a limitation. However, the key limitation around the
measurement of effects is the lack of valid methods for measuring health-related quality of life, and
thus QALYs, in children as young as those in the current study. At the time that the proposal and
protocol were developed, no appropriate methods existed. Nearer the end of the study, the authors
became aware of guidance for the proxy completion of the CHU-9D by parents of children aged
< 5 years (personal communication with the developer of the measure, Dr Katherine Stevens,
University of Sheffield, 25 March 2019), but this was still being tested and its validity for children
as young as those aged 1 or 2 years is uncertain (given questions around worry, sadness and daily
routine). Until appropriate methods for the measurement of health-related quality of life in children of
this age exist, an economic evaluation will continue to prove difficult in very young populations.
To compensate for this limitation, we used a published algorithm to map health state utilities from
clinical outcomes using the SDQ. Mapping is a widely used approach in economic evaluation where
direct measurement of health utilities is not possible,83–85 and is recommended by NICE and the
International Society for Pharmacoeconomics and Outcomes Research (ISPOR).65,86 However, the
validity of the methods used is debated in the literature,87–89 loss of information at each stage of
transformation leads to uncertain estimates and thus potentially erroneous conclusions, and proxy
reporting by parents is also associated with a number of limitations.90,91 The mapping algorithm applied
in the current study was identified in a recent systematic review as the only algorithm that converts
any of the outcomes in the current study to child health utilities.92 However, the algorithm was
developed in Australia with data collected from adolescents; thus, its relevance to much younger
children in the UK is uncertain. Since starting work on this analysis, a second mapping algorithm
has been published that the authors argue is ‘better performing’ and maps from 25 individual items
from the SDQ, as opposed to the five subscales.93 However, the population remains the same
(i.e. Australian adolescents).
The short-term nature of the within-trial analysis is also a limitation as participants are less likely to
incur costs for resource use relating to behavioural problems during this preschool period. Service use,
and thus further costs, are more likely when the child is older. It is difficult to map trajectories without
suitable longitudinal data; most publicly available data sets tend to be cross-sectional, out of date,
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small in terms of sample size, and thus of limited generalisability, and missing key parameters to allow
for calculation of all relevant costs and health state utilities. Furthermore, combining data from multiple
sources to extrapolate results to different populations and over longer periods of time would require
many assumptions and huge uncertainties, and is likely to produce poor estimates for cost-effectiveness
analyses. Although longer-term modelling can be a useful decision tool, it can also be a source of many
biases. This is particularly true for studies in very young children, where the absence of reliable input
data means that surrogate measures must often be used.
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We found clear evidence that a brief, home-based intervention, VIPP-SD, was more effective than
usual care in reducing behaviour problems in this group of children aged 1 and 2 years. The effect
was strongest for children’s conduct problems, with evidence suggesting that most of the effect
was sustained at a 24-month follow-up. This intervention uses video feedback from predominantly
play-based sessions with a caregiver and their child, where the therapist shares feedback to promote
sensitive responding and consistent discipline strategies with parents/caregivers of young children.
For the primary outcome (the interview-based PPACS assessment) at the 5-month post-treatment
assessment, evidence of superiority was found for VIPP-SD. The secondary analysis, which tested the
benefits of the intervention for those participants who received the core number of sessions (i.e. four
sessions or more), showed a larger reduction in behaviour problems. This evidence, showing that
increased exposure to the intervention further intensified its benefits, endorses the positive effect of
the VIPP-SD programme. The VIPP-SD treatment effect was also strongest on the conduct problems
scale of the PPACS assessment rather than the ADHD/hyperkinesis scale. This is particularly of note as
social learning theory and the sensitive discipline component of the VIPP-SD programme specifically
target conduct problems. Thus, these differential effects are in keeping with expectations and it
is instructive to identify that the effects on conduct problems do not appear to extend to ADHD
symptoms. Furthermore, evidence, including new evidence since this trial was designed, strongly
suggests that it is conduct problems in particular that predict worse long-term outcomes for children.94
Relatedly, early childhood conduct problems in particular, rather than hyperkinetic/ADHD problems
only, are associated with greater health-care and criminal justice costs in adulthood.9 Findings on
the two secondary measures of child problems (CBCL and SDQ questionnaires) were consistent in
suggesting an early benefit of VIPP-SD for children’s behaviour problems.
The findings at the longer-term follow-up (24 months post randomisation) indicated a sustained effect
on children’s behaviour problems. The main outcome measure (PPACS) showed a small diminution
of the treatment effect (approximately 15%) over the time between the 5- and 24-month follow-ups.
This meant that the 95% CI did overlap with zero (with a p-value of 0.08), but the consistency of effect
across the main outcome measures suggests that an ongoing treatment benefit is likely. The standardised
effect size for the treatment difference on the total PPACS measure was 0.20 at 5 months post
randomisation and 0.17 at 24 months post randomisation. Although both effect sizes are small, they
are of the magnitude that may be expected to make a real difference for a brief early intervention
rolled out across a large population. Similarly, the effect on the conduct disorder scale at 24 months,
although somewhat reduced (0.30 standardised effect size at 5 months post randomisation and 0.20 at
24 months post randomisation), is likely to represent a meaningful effect of the intervention.
The main findings are consistent with previous, smaller studies of VIPP-SD. A recent meta-analysis32
demonstrated a similar effect size to that seen in the present study for children’s behaviour problems
(0.26) and larger effect sizes for parental sensitivity (0.47). Previous VIPP-SD research also indicates the
intriguing possibility that certain parents and children may be especially sensitive to the benefits of the
intervention and show greater improvements in outcomes – this is known as differential susceptibility.95–97
Data on which to base our original power calculation were limited, and in the original protocol we had
anticipated a larger possible effect size than that seen in the present study. Some caution is therefore
warranted in interpreting these findings. The effect size found for the VIPP-SD intervention in this study
(0.20) is somewhat difficult to interpret for an individual child or family; however, it represents a mean
difference of 2 points on the PPACS measure. As an example, for tantrums, this 2-point difference would
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equate to a change from severe (breaking things) to mild (shouting) or a change in frequency from daily
to once or twice per week. Although tantrums are a normative feature of early childhood, daily tantrums
are not normative and occur in < 10% of preschool-aged children.98
As the first pragmatic trial of VIPP-SD conducted in a routine NHS health-care setting, it is striking
that the effectiveness of the intervention is robust in this setting. The intervention is also highly
acceptable for a psychological treatment as indicated by the high levels of adherence. There was
also positive feedback from families, although this was limited to a small proportion of participating
families. A substantial body of evidence for the effectiveness of several interventions already exists
for childhood behaviour problems; however, this is the first study, to our knowledge, that demonstrates
a beneficial treatment effect in such young children and in a pragmatic trial in routine practice. This is
important as there are many examples of promising interventions for child mental health problems that
do not show a clear benefit over routine care in NHS practice settings, despite some initial evidence
of effectiveness in other, sometimes more tightly controlled, trial conditions.99–101 Consequently, the
findings of this study can be more reliably extrapolated to routine clinical care delivered by NHS staff,
including health visitors and community nursery nurses.
The findings of this study are also able to partly address a potential concern about brief early interventions,
such as VIPP-SD, for childhood behaviour problems, namely whether or not brief interventions are
sufficient to be effective for children with more severe behaviour problems. The findings from this
study suggest that the effect of the intervention was greater in children with more severe behaviour
problems. Children with more severe behaviour problems at the beginning of the study tended to show
more improvement in their behaviour, which inspired for confidence that this predominantly health
visitor-led intervention can benefit families and children who may need it most. The findings suggest
that interventions might be most beneficially targeted at those children with higher levels of behaviour
problems. Similarly, the findings show that the intervention is effective even in children aged 1 year.
The findings also give some confidence that those who may benefit from treatment can be identified
using a simple screening questionnaire (SDQ).42 The high levels of adherence and fidelity of treatment
delivery seen in this pragmatic trial also suggest that this intervention can be reliably and successfully
delivered in routine NHS practice.
There was no benefit of the intervention on other secondary outcome measures of parental mood,
anxiety or relationship adjustment. Parent-mediated interventions often anticipate effects on parental
well-being; however, this evidence suggests that these programmes are unlikely to be sufficiently
powerful in and of themselves to confer benefits on global assessments of parental distress.102
Economic evaluation
The primary economic analysis suggests that VIPP-SD is associated with significantly higher costs than
usual care as a result of the additional cost of the VIPP-SD intervention and greater improvements
in behaviour. When these costs are combined with the differences in PPACS scores that favour the
intervention over usual care, the probability of VIPP-SD being cost-effective compared with usual
care increases as the WTP for improvements in PPACS scores increases, with VIPP-SD having a
higher probability of being cost-effective at WTP values of approximately £800 and above per
1-point improvement in PPACS score (equivalent to 0.10 SD). In theory, this would equate to a
cost of approximately £7920 for 1 SD improvement. As the PPACS is not associated with a WTP
threshold to support decision-making, it is not possible to come to any firm conclusions about the
relative cost-effectiveness of VIPP-SD in the short term. Any judgement of costs needs to be weighed
against the lifetime costs of behaviour problems, estimates for which range from £90,000 per case
for those with subthreshold behaviour problems to £280,000 for those with early conduct disorder.10
Indeed, the long-term costs for conduct disorder in particular are so high that early interventions that
generate even modest improvements could provide a positive return on investment in the long term.10
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The cost of the VIPP-SD intervention was the key cost driver in the cost-effectiveness analyses. It is
difficult to contextualise the cost of the intervention (mean cost £1466) because there is a lack of
publicly available information on the costs of early intervention programmes,103 differences in costing
methods and few cost-effectiveness evaluations of similar early intervention programmes. However,
the costs identified in the current study are lower than the unit costs (£1612–2418) reported from a
group-based parenting intervention (Incredible Years) for preschool aged children delivered in the
UK.104 That study reported that a 1-point improvement on the SDQ would cost £1295 on a 40-point
scale (where 1 point represents 0.14 of the SD of the control group at follow-up).104 Overall, effective
early interventions for preschool-aged children at risk of conduct disorder that cost in the region of
£1500 are seen as relatively low cost.10
It is also noteworthy that intervention costs commonly reduce in the longer term as therapists become
more experienced, and service providers and commissioners benefit from both experience and economies
of scale. In particular, the length of sessions (1.5 hours) in the current trial may reflect the fact that all of
the VIPP-SD trial therapists were new to the intervention and had been trained only recently. Similarly,
the length of sessions in the current trial includes the longer sessions needed to deliver VIPP to two
caregivers in some cases; thus, we would expect the length of sessions to be shorter if VIPP-SD was
delivered to only one caregiver.
Strengths and limitations
A strength of this study is that it is a multisite, pragmatic, RCT that recruited families in routine
health-care settings in urban, suburban and rural settings in the UK. The VIPP-SD intervention was
acceptable to participants in this setting, with very high levels of retention (95%) achieved and very
low levels of missing data. The intervention was largely delivered as intended, with the majority
of assessments indicating that therapy met the necessary threshold for adherence to the manual
and that the vast majority of participants received the full dosage of the programme. The intervention
was delivered by NHS staff in a pragmatic context, and this is the first time, to our knowledge, that
VIPP-SD has been investigated in this context. This is also the largest study of VIPP-SD to date,
the first cost-effectiveness study of VIPP-SD to be attempted and one of the earliest intervention
studies of children demonstrating risk for developing enduring mental health problems in the UK.
The study also benefited from the use of a structured interview to assess the primary outcome, which
is considered the gold standard outcome measure for mental health problems.46 Efforts to maintain
blinding were largely effective and, in the very small number of cases where research assessors were
unblinded, a second researcher rescored the assessment to minimise any risk of bias.
The study had limitations. First, as with many RCTs, the participants in the final sample had a higher
level of education than the general population, such that 64% of participants had a graduate-level
qualification, compared with ≈ 40% of people aged 25–34 years in England (based on the 2011
Census).105 This is notable as low parental education is a risk factor for persistent behaviour problems
in young children.10 As a large proportion of families were recruited from London (where educational
attainment tends to be higher than national levels), caution should be exercised when considering the
generalisability of the study findings to the rest of the UK. In most other respects, the sample was
generally representative of the broad range of communities that participated in the study.
Second, approximately half of those eligible for the trial proceeded to take part. Although this is similar
to the rate of progression seen in many RCTs of psychological intervention96,97 and may relate to taking
part in a clinical trial rather than to taking part in routine intervention, it does suggest that not all
families will engage in this intervention in routine practice, and so alternative forms of help and
provision are will also be necessary.
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Third, we found that not all therapists were able to deliver the intervention, largely because of service
changes that meant that the time planned for delivery of the therapy became restricted. This was evident
in the variation in the number of VIPP-SD cases delivered by individual therapists (range 1–12 cases,
median three cases). Thus, it is possible that the treatment effect observed here is an underestimation of
the effect that may be seen over a longer implementation period as therapists become more experienced.
A limitation of the health economic analysis is the lack of valid methods for measuring health-related
quality of life, and thus QALYs, in young children. As a result, we used a published algorithm to map
health state utilities from clinical outcomes using the SDQ, as mapping is a widely used approach in
economic evaluation where direct measurement of health utilities is not possible and mapping is
recommended by NICE and ISPOR.65,86 However, the validity of the methods used is debated in the
literature,87–89 loss of information at each stage of transformation leads to uncertain estimates and
thus potentially erroneous conclusions, and proxy reporting by parents is also associated with a
number of limitations.90,91 The mapping algorithm applied in the current study was identified in a
recent systematic review as the only algorithm available that converts any of the outcomes included
in the current study to child health utilities.92 However, the algorithm was developed in Australia with
data collected from adolescents and, therefore, its relevance to much younger children in the UK is
uncertain. The short-term nature of the within-trial analysis is also a limitation as participants are less
likely to incur costs for resource use relating to behaviour problems during this preschool period.
Service use, and thus further costs, are more likely in later years.
It is worth noting that there is a lack of evidence for effective preventative interventions for behaviour
problems in very young children and a lack of services delivering interventions in the UK. The findings
of this study do, therefore, offer important evidence to suggest that positive outcomes can be achieved
with the VIPP-SD intervention.
Conclusions
Implications for health care
This is the largest RCT of the VIPP-SD intervention, a brief, home-based intervention for parents
of young children. It is also the first trial to be conducted in a routine NHS setting. The findings
demonstrate that the intervention is effective at reducing behaviour problems in very young children
(aged 1 or 2 years) and there is strong potential for the intervention to be delivered successfully by
NHS staff in routine practice. There was a positive endorsement of the home-based delivery format by
families and the study shows that the intervention can be delivered by health visitors and community
nursery nurses. The intervention could provide an important means of early detection and treatment
of very early mental health problems in the community before these problems become established
and more difficult to treat.
The presented study is also one of the first pragmatic trials in the UK to demonstrate an effect of
an early intervention for psychological difficulties in young children. It is well established in empirical
and policy forums that the scope for benefit from early preventative intervention is huge.33–35 What
is largely lacking at present is evidence of effective programmes. The findings of the present study
represent a significant step towards this. It is particularly striking that the intervention is effective
in children as young as 1 year of age, as well as those with more severe behaviour problems. Although
the mean effect is small in magnitude, it is notable that it can be achieved this early in life, when
there are few effective treatments. This is important, as early benefits could act to potentiate the
effects of interventions delivered at later developmental points for those children at greatest risk
of conduct disorder.38
The VIPP-SD intervention can be delivered successfully in routine NHS care and to specified groups
of children who may benefit most, who can be identified using a simple, brief screening questionnaire.
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There is significant scope for the intervention to be incorporated relatively easily in routine practice.
The findings are especially notable given that there are no standard care pathways in the NHS for
early-onset behaviour problems.
Implications for future research
The potential prize of successful early preventative intervention is substantial, namely the opportunity to
prevent future suffering and to significantly reduce the large economic burden associated with mental
health problems across many sectors of government, including health, education, social care and future
employment. The findings of the present study suggest that there is hope for early interventions to be
able to deliver positive outcomes in real-world pragmatic settings. Although these are findings in young
children, findings from a large body of research suggest that there are significant long-term risks of
untreated behaviour problems.2,5
We suggest four key implications for future research.
First, further study is needed to assess the potential longer-term outcomes of interventions such
as VIPP-SD. Our understanding to date is largely based on modelling studies or extrapolation from
findings of interventions in older children, which may or may not turn out to be accurate when applied
to younger children. Longer-term follow-up of early interventions could greatly improve estimates of
cost-effectiveness as costs are more likely to accrue in later years.
Second, further study of other interventions and other time points for intervention is necessary.
Research suggests that a single intervention delivered in isolation is unlikely to be a panacea for
behaviour problems. Rather, repeated, efficient interventions delivered at different ages are likely to
be necessary to most effectively reduce the future burden of mental health problems across the life
course.37–39 In this context, the findings of the present study are important, as a corollary of the need
for staged interventions is the identification of evidence-based programmes that can be delivered to
very young children at the first onset of behaviour problems. We already have some understanding of
different interventions that have been shown to be effective for older children, but this is such an
important area for practice that greater knowledge is needed. This further study will need to include
assessment of when and if booster sessions are needed after an initial brief intervention. Similarly,
it will be important to test whether or not the initial effects of early intervention such as VIPP-SD
can be sustained or further potentiated when followed by later evidence-based interventions. From
a cost-effectiveness point of view, the development of a ‘whole disease model’ that can model
interventions across different ages simultaneously may prove to be of value.106
Third, further study is needed of how the underlying mechanisms of effective early interventions
such as VIPP-SD work and for whom they may work best. The VIPP-SD intervention benefits from a
clearly articulated conceptual framework that targets two key parenting behaviours: sensitivity and
discipline. Identifying the contribution of these components to the programme’s effects will allow
better refinement of the intervention, focus on the most effective components and, therefore, make
treatment more effective and potentially more efficient for delivery at scale. Future research could
also adopt a differential susceptibility perspective to investigate whether or not the intervention is
more effective in those parents and children who tend to benefit more from improvements in their
environment. Taken together, this research may allow us to move to a position where we can offer
interventions to those for whom we know they work best.
Fourth, there is a need for further methodological development that can support economic evaluations
of early interventions targeting young children. Specifically, there is a need for valid tools for measuring
health-related quality of life, and thus QALYs, in very young children, as well as mixed-methods approaches
that can capture a range of outcomes (e.g. acceptability of interventions) that are likely to be important to
decision-makers and commissioners.84,85
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In conclusion, this study suggests that we have an early intervention that is effective in reducing
behaviour problems in young children, is highly acceptable to parents and can be successfully delivered
in routine NHS practice. There is some evidence of continuing benefit of the VIPP-SD intervention
24 months later, but we can be less certain about its value for money. Early intervention represents
a huge opportunity for the future positive development of young children, and a lack of effective
interventions is one of the key problems holding back the field. The results of this study provide a
significant step forward and represent a new opportunity for effective early childhood intervention to
prevent enduring mental health problems.
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Appendix 1 Primary outcome: Preschool
Parental Account of Children’s Symptoms
More information about the measure is available on request from the corresponding author.Additional detail is also available in Chen and Taylor.107
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Appendix 2 Additional detail regarding
multiple imputation analysis
There is no information on treatment of missing values in the manuals for PPACS, our primaryoutcome measure. A multiple imputation was used on the individual questions in each questionnaire
at baseline and at follow-up to optimise our treatment of missing data. Any child who has a PPACS
at follow-up with at least 50% of the questions completed was included in this multiple imputation
PPACS outcome analysis. We based our imputation on completed questions and subscale scores from
the PPACS interview at outcome and total scores at earlier time points. For multiple imputation at
baseline, we based our imputation on completed questions and subscale scores from the PPACS
interview at baseline only. The primary analysis also incorporated multiple imputation for anyone whose
PPACS at outcome was completely missing (or had fewer items completed than the threshold). At the
5-month follow-up, these were imputed based on randomised group, sex of child, age of child at the
5-month assessment, baseline PPACS, CBCL and SDQ scores. At the 2-year follow-up, these were
imputed based on randomised group, sex of child, age of child at the 2-year assessment, and PPACS,
CBCL and SDQ scores (at the 5-month follow-up, if available, or else using these PPACS, CBCL and
SDQ scores at baseline).
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Appendix 3 Participant recruitment by
month from trial commencement to
recruitment target (n = 300)
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FIGURE 12 Participant recruitment by month from trial commencement to recruitment target.
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Appendix 4 Secondary caregiver analysis











Sex (male), n (%) 23 (88) 20 (80) 111 (95) 110 (96)
Age (years), mean (SD) 35.4 (6.4) 38.3 (8.9) 37.1 (7.2) 37.6 (6.9)
Parental status, n (%)
Parent (including step or adoptive) 26 (100) 23 (92) 116 (99.1) 113 (98.3)
Other 0 (0) 2 (8) 1 (0.9) 2 (1.7)
Ethnicity, n (%)
Asian 3 (12) 2 (8) 12 (10) 10 (9)
Black 1 (4) 2 (8) 9 (8) 13 (11)
Mixed ethnicity 2 (8) 1 (4) 6 (5) 3 (3)
White 19 (73) 17 (68) 85 (73) 84 (73)
Other 1 (4) 3 (12) 5 (4) 5 (4)
Relationship status, n (%)
Married/civil partnership/cohabiting 25 (96) 24 (96) 103 (88) 104 (90)
Divorced/widowed/legally separated 0 (0) 1 (4) 1 (1) 2 (2)
Single and none of the above 0 (0) 0 (0) 5 (4) 8 (7)
In a relationship but not cohabiting 1 (4) 0 (0) 8 (7) 1 (1)
Employment status, n (%)
Employed 26 (100) 16 (64) 92 (79) 88 (77)
Paid parental leave 0 (0) 0 (0) 0 (0) 0 (0)
Self-employed 0 (0) 5 (20) 20 (17) 23 (20)
Full-time student 0 (0) 0 (0) 0 (0) 0 (0)
Looking after home and children 0 (0) 4 (16) 5 (4) 4 (3)
Highest qualification,a n (%)
GCSE or lower 2 (8) 3 (12) 22 (19) 19 (17)
A level/NVQ/BTEC 4 (15) 5 (20) 26 (22) 23 (20)
Graduate 20 (77) 17 (68) 68 (59) 72 (63)
A level, Advanced level; BTEC, Business and Technology Education Council; GCSE, General Certificate of Secondary
Education; NVQ, National Vocational Qualification.
a Data were missing for one participant in each group for non-participating caregivers for this variable.
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TABLE 25 Primary ITT analysis of adjusted mean difference on secondary outcomes of children’s behaviour problems
(total scores) at the 5- and 24-month follow-ups reported by participating secondary caregivers
Outcome
Trial group
Mean differencea (95% CI) Effect sizeb (95% CI) p-valuea
VIPP-SD Usual care
n Mean (SD) n Mean (SD)
CBCLc total score – secondary caregiver report
Baseline 26 43.8 (23.6) 25 37.1 (15.2)
5 months 24 35.3 (19.7) 24 31.4 (14.2) –5.2 (–13.3 to 3.0) –0.36 (–0.94 to 0.21) 0.21
24 months 23 33.0 (23.1) 24 31.5 (16.4) 1.61 (–7.78 to 10.99) 0.10 (–0.48 to 0.67) 0.73
SDQc total score – secondary caregiver report
Baseline 26 13.9 (5.0) 25 11.3 (5.7)
5 months 24 11.2 (4.7) 24 10.5 (3.7) –0.78 (–2.89 to 1.33) –0.21 (–0.78 to 0.36) 0.46
24 months 23 10.3 (6.0) 24 10.6 (5.6) 2.32 (–0.78 to 5.41) 0.41 (–0.14 to 0.96) 0.14
a Difference in mean is difference between treatment groups from linear regression analysis of the outcome measure
on the baseline score of that same measurement, on treatment centre, on randomised group, on length of follow-up,
on age of child and on number of parents/caregivers participating (all treated as fixed effects). Positive differences
represent greater adjusted decreases in symptoms in the VIPP than in the usual-care group.
b Effect size is standardised difference in mean (adjusted as above). This is the difference in mean divided by the SD of
controls at follow-up.
c Higher scores indicate higher problems.




Mean differenceb (95% CI) Effect sizec (95% CI) p-value
VIPP-SD Usual care
n Mean (SD) n Mean (SD)
CBCLd – secondary caregiver reported
Baseline 26 43.8 (23.6) 25 37.1 (15.2)
5 months 24 35.3 (19.7) 24 31.4 (14.2) –8.16 (–17.2 to 0.90) –0.58 (–1.21 to 0.06) 0.08
24 monthse 23 33.0 (23.1) 24 31.5 (16.4) 1.61 (–7.78 to 10.99) 0.10 (–0.48 to 0.67) 0.73
SDQd – secondary caregiver reported
Baseline 26 13.9 (5.0) 25 11.3 (5.7)
5 months 24 11.2 (4.7) 24 10.5 (3.7) –0.87 (–2.89 to 1.15) –0.24 (–0.78 to 0.31) 0.40
24 monthse 23 10.3 (6.0) 24 10.6 (5.6) 2.32 (–0.78 to 5.41) 0.41 (–0.14 to 0.96) 0.14
a CACE results are based on the assumption that there is no effect of being randomised to VIPP-SD, or of receiving
one, two or three VIPP-SD visits. Receiving four, five or six VIPP-SD visits counts as receiving the intervention.
b Difference in mean is difference between treatment groups from linear regression analysis of the outcome measure
on the baseline score of that same measurement, on treatment centre, on randomised group, on length of follow-up,
on age of child and on number of parents/caregivers participating (all treated as fixed effects). Positive differences
represent greater adjusted decreases in symptoms in the VIPP-SD than in the usual-care group.
c Effect size is standardised difference in mean (adjusted as above). This is the difference in mean divided by the SD of
controls at follow-up.
d Higher scores represent higher levels of behaviour problems.
e At the 24-month follow-up, all families with two participating caregivers who were allocated to the VIPP-SD group
received the intervention in practice. Hence, these CACE results are identical to the ITT results.
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(95% CI) Effect sizeb (95% CI) p-value
VIPP-SD Usual care
n Mean (SD) n Mean (SD)
CBCLc total score: female caregiver reported
Baseline 146 41.2 (21.6) 147 42.6 (21.4)
5 months 135 32.7 (20.7) 143 37.8 (21.1) 3.97 (0.57 to 7.36) 0.19 (0.03 to 0.35) 0.02
24 months 136 30.9 (23.8) 142 36.1 (23.8) 3.62 (–1.11 to 8.35) 0.15 (–0.05 to 0.35) 0.13
CBCLc total score: male caregiver reported
Baseline 31 40.8 (23.6) 25 37.8 (13.8)
5 months 29 33.6 (19.2) 24 27.5 (11.9) –7.71 (–14.83 to -0.59) –0.65 (–1.25 to -0.05) 0.03
24 months 28 31.1 (21.1) 24 25.6 (11.5) –4.75 (–12.88 to 3.37) –0.41 (–1.12 to 0.29) 0.24
SDQd total score: female caregiver reported
Baseline 145 14 (4.7) 147 14.1 (4.7)
5 months 135 11.4 (5.1) 143 12.3 (5.2) 1.05 (0.06 to 2.05) 0.20 (0.01 to 0.39) 0.04
24 months 136 10.4 (5.5) 142 11.1 (5.9) 0.59 (–0.56 to 1.75) 0.10 (–0.09 to 0.3) 0.31
SDQd total score: male caregiver reported
Baseline 31 13.3 (5.2) 25 10.9 (5.4)
5 months 29 11.0 (4.7) 24 9.8 (3.4) –1.37 (–3.41 to 0.66) –0.41 (–1.01 to 0.2) 0.18
24 months 28 10.4 (5.4) 24 8.8 (3.6) –0.01 (–2.53 to 2.52) 0.00 (–0.71 to 0.71) 1.00
CBCLc externalising subscale: female caregiver reported
Baseline 146 16.8 (8) 147 17.5 (8.5)
5 months 135 13.4 (8.2) 143 15.4 (8.6) 1.48 (–0.03 to 2.98) 0.17 (0.00 to 0.35) 0.05
24 months 136 11.7 (8.9) 142 13.6 (9.7) 1.16 (–0.71 to 3.02) 0.12 (–0.07 to 0.31) 0.22
CBCLc externalising subscale: male caregiver reported
Baseline 31 16.1 (8.8) 25 14.9 (6.3)
5 months 29 13.6 (8.9) 24 11.5 (4.6) –2.90 (–6.55 to 0.75) –0.64 (–1.44 to 0.16) 0.12
24 months 28 11.8 (8.8) 24 10.5 (6.0) –0.96 (–5.09 to 3.17) –0.16 (–0.85 to 0.53) 0.64
CBCLc internalising subscale: female caregiver reported
Baseline 146 9.1 (7.2) 147 9.6 (7.5)
5 months 135 7.3 (6.5) 143 8.6 (6.8) 1.14 (–0.02 to 2.30) 0.17 (0.00 to 0.34) 0.05
24 months 136 8.3 (8.4) 142 9.2 (7.6) 0.49 (–1.15 to 2.13) 0.06 (–0.15 to 0.28) 0.55
CBCLc internalising subscale: male caregiver reported
Baseline 31 8.4 (7.4) 25 8.1 (5.4)
5 months 29 7.0 (5.4) 24 5.7 (5.2) –1.23 (–3.98 to 1.51) –0.24 (–0.77 to 0.29) 0.37
24 months 28 7.9 (7.6) 24 5.6 (3.5) –2.23 (–4.90 to 0.44) –0.63 (–1.38 to 0.12) 0.10
continued
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TABLE 27 Secondary outcomes on child behaviour according to the perception of male and female caregivers:




(95% CI) Effect sizeb (95% CI) p-value
VIPP-SD Usual care
n Mean (SD) n Mean (SD)
SDQd externalising subscale: female caregiver reported
Baseline 145 9.5 (2.9) 147 9.5 (3.5)
5 months 135 7.6 (3.4) 143 8.3 (3.8) 0.76 (0.06 to 1.46) 0.20 (0.02 to 0.39) 0.03
24 months 136 7.0 (3.6) 142 7.6 (4.2) 0.56 (–0.23 to 1.35) 0.13 (–0.05 to 0.32) 0.16
SDQd externalising subscale: male caregiver reported
Baseline 31 9.0 (3.5) 25 7.6 (3.1)
5 months 29 7.4 (3.6) 24 6.8 (2.8) –0.89 (–2.59 to 0.81) –0.32 (–0.92 to 0.29) 0.30
24 months 28 6.6 (3.6) 24 6.1 (3.4) 0.22 (–1.93 to 2.37) 0.07 (–0.58 to 0.71) 0.84
a Difference in mean is difference between treatment groups from linear regression analysis of the outcome measure
on the baseline score of that same measurement, on treatment centre, on randomised group, on length of follow-up,
on age of child and on number of parents/caregivers participating (all treated as fixed effects). Positive differences
represent greater adjusted decreases in symptoms in the VIPP-SD than in the usual-care group, with the exception
of the CBCL prosocial scale (see footnote c).
b Effect size is standardised difference in mean (adjusted as above). This is the difference in mean divided by the SD of
controls at follow-up.
c Higher scores on all scales represent higher levels of behaviour problems, with the exception of the prosocial scale,
where higher scores indicate lower levels of problems.
d Higher scores represent higher levels of behaviour problems.
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
76
Appendix 5 Supplementary analysis
TABLE 28 Sensitivity analyses for lack of adjustment for length of follow-up: primary and secondary outcomes on child
behaviour – ITT analysis
Outcome
Trial group
Mean differencea (95% CI) Effect sizeb (95% CI) p-value
VIPP-SD Usual care
n Mean (SD) n Mean (SD)
PPACSc
Baseline 151 33.5 (9.0) 149 32.4 (10.6)
5 months 140 28.8 (9.2) 146 30.3 (9.9) 2.02 (0.24 to 3.80) 0.20 (0.02 to 0.38) 0.03
24 months 140 23.1 (8.2) 142 24.7 (9.9) 1.94 (–0.05 to 3.92) 0.20 (–0.01 to 0.4) 0.06
CBCLc
Baseline 151 40.7 (21.7) 149 42.7 (21.1)
5 months 140 32.5 (20.6) 145 37.2 (21.0) 2.48 (–0.5 to 5.46) 0.12 (–0.02 to 0.26) 0.10
24 months 141 30.6 (23.4) 144 35.3 (23.7) 3.29 (–1.34 to 7.91) 0.14 (–0.06 to 0.33) 0.16
SDQc
Baseline 150 13.8 (4.8) 149 14.0 (4.7)
5 months 140 11.3 (5.1) 145 12.2 (5.2) 0.72 (–0.15 to 1.6) 0.14 (–0.03 to 0.31) 0.10
24 months 141 10.4 (5.4) 144 10.9 (5.8) 0.38 (–0.73 to 1.5) 0.07 (–0.13 to 0.26) 0.50
a Difference in mean is difference between treatment groups from linear regression analysis of the outcome measure
on the baseline score of that same measurement, on treatment centre, on randomised group, on age of child and on
number of parents/caregivers participating (all treated as fixed effects). Positive differences represent greater
decreases in the VIPP-SD than in the usual-care group.
b Effect size is standardised difference in mean (adjusted as above). This is the difference in mean divided by the SD of
controls at follow-up.
c Higher scores represent higher behaviour problems.
DOI: 10.3310/hta25290 Health Technology Assessment 2021 Vol. 25 No. 29
© 2021 O’Farrelly et al. This work was produced by O’Farrelly et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the
title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
77






















Sex (male), n (%) 67 (50) 4 (36) 7 (64) 60 (43) 1 (33) 2 (29)
Age (months), mean (SD) 22.5 (6.9) 25.1 (5.3) 24.6 (6.0) 23.1 (6.5) 24.0 (4.4) 24.6 (6.1)
Primary caregiver characteristic
Sex (male), n (%) 8 (6) 0 (0) 0 (0) 5 (4) 0 (0) 0 (0)
Age (years), mean (SD) 34.4 (5.3) 30.1 (5.4) 26.1 (4.5) 34.8 (5.9) 30.0 (6.1) 34.4 (5.5)
Ethnicity, n (%)
Asian 14 (11) 1 (9) 0 (0) 14 (10) 1 (33) 1 (14)
Black 3 (2) 0 (0) 0 (0) 15 (11) 0 (0) 0 (0)
Mixed ethnicity 10 (8) 1 (9) 0 (0) 10 (7) 0 (0) 1 (14)
White 98 (74) 9 (82) 11 (100) 99 (70) 1 (33) 4 (57)
Other 8 (6) 0 (0) 0 (0) 3 (2) 1 (33) 1 (14)
Relationship status, n (%)
Married/civil partnership/cohabiting 115 (86) 8 (73) 7 (64) 121 (86) 3 (100) 5 (71)
Divorced/widowed/legally separated 1 (1) 0 (0) 0 (0) 4 (3) 0 (0) 0 (0)
Single and none of the above 10 (8) 2 (18) 2 (18) 15 (11) 0 (0) 2 (29)
In a relationship but not cohabiting 7 (5) 1 (9) 2 (18) 1 (1) 0 (0) 0 (0)
Employment status, n (%)
Employed 60 (45) 4 (36) 4 (36) 61 (43) 2 (67) 3 (43)
Paid parental leave 6 (5) 0 (0) 0 (0) 10 (7) 0 (0) 0 (0)
Self-employed 18 (14) 2 (18) 0 (0) 11 (8) 0 (0) 1 (14)
Student 3 (2) 0 (0) 0 (0) 7 (5) 0 (0) 0 (0)
Looking after home and children 46 (35) 5 (45) 7 (64) 52 (37) 1 (33) 3 (43)
Highest qualification, n (%)
GCSE or lower 12 (9) 3 (27) 3 (27) 13 (9) 0 (0) 1 (14)
A level/NVQ/BTEC 34 (26) 5 (45) 4 (36) 32 (23) 1 (33) 4 (57)
Graduate 87 (65) 3 (27) 4 (36) 96 (68) 2 (67) 2 (29)
A level, Advanced level; BTEC, Business and Technology Education Council; GCSE, General Certificate of Secondary
Education; NVQ, National Vocational Qualification.
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TABLE 30 Baseline and 5- and 24-month follow-up values of outcome measures in those with missing PPACS data
at follow-up
Outcome



















Baseline 33.2 (9) 36.5 (8.7) 37.9 (10.8) 32 (10.5) 37.3 (5.1) 36.7 (15.9)
5-month follow-up 28.5 (9) 34.9 (12.1) 30.4 (9.9) 27.5 (12.8)
24-month follow-up 23.2 (8.3) 21.5 (7.9) 24.6 (9.9) 30 (–)
CBCLa
Baseline 39.8 (21.2) 52.1 (27.7) 47.1 (27.2) 42.5 (21.1) 40.7 (12.3) 46.0 (23.8)
5-month follow-up 32.4 (20.6) 34.3 (22.5) 37.1 (21) 43.3 (21.7)
24-month follow-up 30.6 (23.7) 30.3 (20.2) 23.2 (–) 35.2 (23.7) 25.6 (13.6) 41.5 (36.1)
SDQa
Baseline 13.7 (4.8) 14.9 (5.2) 16.3 (5.0) 14.0 (4.7) 12.2 (4.2) 14.4 (4.9)
5-month follow-up 11.2 (5.1) 14 (5.2) 12.2 (5.3) 13.5 (3.0)
24-month follow-up 10.4 (5.5) 10.3 (4.7) 12 (–) 10.9 (5.7) 7.0 (1.4) 16.0 (11.3)
Parenting Scaleb
Baseline 3.0 (0.5) 2.8 (0.7) 2.7 (0.4) 3.0 (0.6) 2.7 (0.5) 2.9 (0.5)
5-month follow-up 2.9 (0.5) 2.8 (0.5) 2.9 (0.6) 2.6 (0.2)
24-month follow-up 3.0 (0.5) 3.1 (0.7) 2.8 (–) 3.0 (0.6) 2.8 (0.4) 3.7 (0.8)
PHQ-9c
Baseline 4.1 (3.8) 5.1 (4.8) 6.4 (4.8) 3.9 (3.6) 5.3 (6.8) 10.9 (10.4)
5-month follow-up 3.9 (4.4) 4.3 (4.9) 4.0 (4.4) 11.6 (8.0)
24-month follow-up 4.1 (4.6) 2.3 (3.0) 5.0 (–) 3.9 (4.0) 3.0 (1.4) 11.0 (12.7)
GAD-7c
Baseline 4.9 (4.4) 3.6 (4.2) 4.4 (3.8) 4.7 (4.2) 5.3 (5.0) 5.3 (4.4)
5-month follow-up 4.2 (4.4) 4.1 (4.7) 3.9 (4.0) 6.4 (4.8)
24-month follow-up 4.2 (4.7) 1.9 (2.1) 5.0 (–) 4.1 (4.0) 5.0 (2.8) 11.0 (5.7)
RDASd
Baseline 49.8 (8.1) 45.8 (6.9) 44.9 (10.1) 50.4 (8.9) 59.4 (2.2) 48.2 (16.1)
5-month follow-up 49.3 (9.4) 51.0 (9.1) 49.9 (9.7) 43.7 (15.5)
24-month follow-up 50 (8.2) 54.2 (6.4) 48.0 (–) 50.3 (7.2) 56.0 (8.5) 50.0 (–)
a Higher scores represent higher behaviour problems.
b Higher scores indicate more ineffective parenting strategies.
c Higher scores represent higher levels of behaviour problems.
d Higher scores indicate greater relationship satisfaction and lower scores indicate greater relationship distress.
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Appendix 6 Subgroup analysis
Subgroup
−8 −6 −4 −2 0 2 4 6 8
Favours usual-care Favours VIPP-SD
Difference in mean PPACS score by treatment group at 5-month follow-up (adjusted)
Age of child at baseline, prespecif ied
1 year
2 years
Number of participating caregivers, prespecif ied
One caregiver
Two caregivers





Fidelity when randomised to VIPP-SD, post hoc
0−3 intervention visits
Intervener f idelity: 2.5−3.4
Intervener f idelity: 3.5−4.4
Intervener f idelity: 4.5−5
5-month adjusted
difference in mean
PPACS score (95% CI)
2.91 (0.06 to 5.76)
2.79 (0.63 to 4.94)
2.80 (−0.96 to 6.56)
1.49 (−2.86 to 5.84)
3.38 (−0.39 to 7.15)
1.44 (−1.09 to 3.97)
3.51 (0.88 to 6.14)
2.87 (−0.56 to 6.30)
1.82 (−1.04 to 4.68)
−2.61 (−7.71 to 2.50)
−0.71 (−6.23 to 4.80)
−0.60 (−5.26 to 4.06)
FIGURE 13 Subgroup analysis for baseline behaviour based on quartiles of externalising scores on the SDQ at the
5-month follow-up.
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Subgroup
Age of child at baseline, prespecif ied
1 year
2 years
Number of participating caregivers, prespecif ied
One caregiver
Two caregivers





Fidelity when randomised to VIPP-SD, post hoc
0−3 intervention visits
Intervener f idelity: 2.5−3.4
Intervener f idelity: 3.5−4.4
Intervener f idelity: 4.5−5 2.66 (−0.79 to 6.10)
1086420−2−4−6−8
Difference in mean PPACS score by treatment group at 24-month follow-up (adjusted)
24-month adjusted
difference in mean
PPACS score (95% CI)
1.34 (−1.39 to 4.07)
2.03 (−0.98 to 5.05)
2.19 (0.00 to 4.39)
1.98 (−1.70 to 5.66)
2.61 (−1.38 to 6.59)
1.44 (−1.10 to 3.98)
3.47 (0.83 to 6.12)
3.20 (−1.27 to 7.67)
−0.59 (−5.40 to 4.22)
−1.28 (−6.59 to 4.03)
−0.64 (−5.31 to 4.03)
FIGURE 14 Subgroup analysis for baseline behaviour based on quartiles of externalising scores on the SDQ at the
24-month follow-up.
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Appendix 7 Breakdown of protocol
deviations and violations
The primary reason for protocol deviations during the trial was missing data. This happened whenfamilies were able to complete only part of an assessment (e.g. because it was carried out over the
telephone), the parent/child did not consent/assent to specific parts of data collection, or, in a small
number of cases, faulty equipment meant that the data could not be collected. Further to this, two
enrolment errors occurred when participants were erroneously enrolled under the incorrect NHS site.
In each case, the case was terminated on the eCRF, the participant was enrolled to the correct site and
they were assigned a new participant ID. Another enrolment error related to a family being enrolled as
having one participating caregiver when there were, in fact, two participating caregivers in the family.
Protocol violations mostly occurred when participants allocated to the treatment group did not take
up any VIPP-SD sessions. Further to this, two protocol violations occurred when participants met the
trial’s exclusion criteria following enrolment to the trial. One family (allocated to the usual-care group)
reported receiving six sessions of an individualised video-feedback intervention during the study.
Another family was participating in active family court proceedings at the 24-month time point.
Table 31 shows a breakdown of all protocol deviations and violations.
TABLE 31 Occurrence of protocol deviations and violations
Deviation/violation type n
Protocol deviations
Participant had missing data 45
Participant did not complete one or more follow-up assessments 28
Enrolment error 3
Protocol violations
Participant did not take up any VIPP-SD treatment 12
Participant met exclusion criteria following enrolment 2
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